WO2023008936A1 - 종양 예방 또는 치료용 약학 조성물 및 이의 용도 - Google Patents
종양 예방 또는 치료용 약학 조성물 및 이의 용도 Download PDFInfo
- Publication number
- WO2023008936A1 WO2023008936A1 PCT/KR2022/011149 KR2022011149W WO2023008936A1 WO 2023008936 A1 WO2023008936 A1 WO 2023008936A1 KR 2022011149 W KR2022011149 W KR 2022011149W WO 2023008936 A1 WO2023008936 A1 WO 2023008936A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- imidazo
- dihydro
- antibody
- pyridin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 267
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 51
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 84
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 84
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 84
- 230000019491 signal transduction Effects 0.000 claims abstract description 78
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract description 75
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 75
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims abstract description 41
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 4
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 143
- 150000003384 small molecules Chemical class 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 73
- 239000012634 fragment Substances 0.000 claims description 52
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 41
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 claims description 40
- 206010009944 Colon cancer Diseases 0.000 claims description 36
- 201000001441 melanoma Diseases 0.000 claims description 35
- 201000007270 liver cancer Diseases 0.000 claims description 29
- 208000014018 liver neoplasm Diseases 0.000 claims description 29
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 28
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 28
- 201000010881 cervical cancer Diseases 0.000 claims description 28
- -1 tert-butyl (4-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)phenyl) carbamates Chemical class 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 21
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 21
- 206010039491 Sarcoma Diseases 0.000 claims description 20
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 17
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 17
- 108091023037 Aptamer Proteins 0.000 claims description 16
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 14
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 14
- 206010005003 Bladder cancer Diseases 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 9
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 9
- 108091008605 VEGF receptors Proteins 0.000 claims description 9
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 9
- 108091008794 FGF receptors Proteins 0.000 claims description 7
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims description 5
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims description 5
- FPKHCAHBTFJUMY-UHFFFAOYSA-N 2-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]thieno[3,2-c]pyridine Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2SC3=CC=NC=C3C=2)=N1 FPKHCAHBTFJUMY-UHFFFAOYSA-N 0.000 claims description 4
- SHZQEVYCVBKDPM-UHFFFAOYSA-N 6-[2-(6-methylpyridin-2-yl)-1,5,6,7-tetrahydroimidazo[1,2-a]pyrimidin-3-yl]quinoxaline Chemical compound CC1=CC=CC(C2=C(N3CCCNC3=N2)C=2C=C3N=CC=NC3=CC=2)=N1 SHZQEVYCVBKDPM-UHFFFAOYSA-N 0.000 claims description 4
- FJIQQNAXYJEMTM-UHFFFAOYSA-N 6-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]-1,3-benzothiazole Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3SC=NC3=CC=2)=N1 FJIQQNAXYJEMTM-UHFFFAOYSA-N 0.000 claims description 4
- QNFZWKYTQYUUBX-UHFFFAOYSA-N 6-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]quinoline Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3C=CC=NC3=CC=2)=N1 QNFZWKYTQYUUBX-UHFFFAOYSA-N 0.000 claims description 4
- JCUXUMWFDOXBEK-UHFFFAOYSA-N 6-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]quinoxaline Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3N=CC=NC3=CC=2)=N1 JCUXUMWFDOXBEK-UHFFFAOYSA-N 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 201000009047 Chordoma Diseases 0.000 claims description 4
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- BMXBEGWDGOVWJX-UHFFFAOYSA-N n,n-dimethyl-2-[7-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]quinoxalin-2-yl]oxyethanamine Chemical compound C=1C2=NC(OCCN(C)C)=CN=C2C=CC=1C(N1CCNC1=N1)=C1C1=CC=CC(C)=N1 BMXBEGWDGOVWJX-UHFFFAOYSA-N 0.000 claims description 4
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims description 3
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims description 3
- 206010073360 Appendix cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010014967 Ependymoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000002511 pituitary cancer Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- MUGBJGXJBQQVGT-UHFFFAOYSA-N 1-[6-(6-methylpyridin-2-yl)-5-quinoxalin-6-yl-2,3-dihydroimidazo[1,2-a]imidazol-1-yl]ethanone Chemical compound CC(=O)N1CCN(C=2C=3C=C4N=CC=NC4=CC=3)C1=NC=2C1=CC=CC(C)=N1 MUGBJGXJBQQVGT-UHFFFAOYSA-N 0.000 claims description 2
- IONRQTOKXUNTDQ-UHFFFAOYSA-N 1-acetyl-6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydroimidazo[1,2-a]imidazole-2-carbonitrile Chemical compound CC(=O)N1C(C#N)CN(C=2C=3SC4=CC=NC=C4C=3)C1=NC=2C1=CC=CC(C)=N1 IONRQTOKXUNTDQ-UHFFFAOYSA-N 0.000 claims description 2
- BIHVICZBGYKDAI-UHFFFAOYSA-N 2-methoxy-7-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]quinoxaline Chemical compound C=1C2=NC(OC)=CN=C2C=CC=1C(N1CCNC1=N1)=C1C1=CC=CC(C)=N1 BIHVICZBGYKDAI-UHFFFAOYSA-N 0.000 claims description 2
- NDPIDAARYDRSAT-UHFFFAOYSA-N 2-methyl-6-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]quinoline Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3C=CC(C)=NC3=CC=2)=N1 NDPIDAARYDRSAT-UHFFFAOYSA-N 0.000 claims description 2
- SGVNXGNPLLXNFL-UHFFFAOYSA-N 4-[4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]phenyl]morpholine Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=CC(=CC=2)N2CCOCC2)=N1 SGVNXGNPLLXNFL-UHFFFAOYSA-N 0.000 claims description 2
- NRISDDDUEBEBFY-UHFFFAOYSA-N 4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]aniline Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=CC(N)=CC=2)=N1 NRISDDDUEBEBFY-UHFFFAOYSA-N 0.000 claims description 2
- XYWDBVUXOUHJAS-UHFFFAOYSA-N 4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]benzonitrile Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=CC(=CC=2)C#N)=N1 XYWDBVUXOUHJAS-UHFFFAOYSA-N 0.000 claims description 2
- VDLOCFPIAQDKPZ-UHFFFAOYSA-N 4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]quinoline Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C3=CC=CC=C3N=CC=2)=N1 VDLOCFPIAQDKPZ-UHFFFAOYSA-N 0.000 claims description 2
- XJFTUKYUEJJILA-UHFFFAOYSA-N 5-(1-benzothiophen-5-yl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3C=CSC3=CC=2)=N1 XJFTUKYUEJJILA-UHFFFAOYSA-N 0.000 claims description 2
- YICOLWMSTIAXMI-UHFFFAOYSA-N 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3OCCOC3=CC=2)=N1 YICOLWMSTIAXMI-UHFFFAOYSA-N 0.000 claims description 2
- NDVJMDMHMYTYBX-UHFFFAOYSA-N 5-(3,5-dimethoxyphenyl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound COC1=CC(OC)=CC(C=2N3CCNC3=NC=2C=2N=C(C)C=CC=2)=C1 NDVJMDMHMYTYBX-UHFFFAOYSA-N 0.000 claims description 2
- HYXXYOAGCLVLPP-UHFFFAOYSA-N 5-(3-methylphenyl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound CC1=CC=CC(C=2N3CCNC3=NC=2C=2N=C(C)C=CC=2)=C1 HYXXYOAGCLVLPP-UHFFFAOYSA-N 0.000 claims description 2
- LNBWRTUIBRIIPV-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=CC(F)=CC=2)=N1 LNBWRTUIBRIIPV-UHFFFAOYSA-N 0.000 claims description 2
- IYDNMQNESHXSIZ-UHFFFAOYSA-N 5-(4-methoxyphenyl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2N=C(C)C=CC=2)N=C2N1CCN2 IYDNMQNESHXSIZ-UHFFFAOYSA-N 0.000 claims description 2
- LVQAMCOGXCZIDP-UHFFFAOYSA-N 5-[4-(4-methylpiperazin-1-yl)phenyl]-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound C1CN(C)CCN1C1=CC=C(C=2N3CCNC3=NC=2C=2N=C(C)C=CC=2)C=C1 LVQAMCOGXCZIDP-UHFFFAOYSA-N 0.000 claims description 2
- GTWAYRJZLGVEND-UHFFFAOYSA-N 5-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]-1,3-benzoxazole Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3N=COC3=CC=2)=N1 GTWAYRJZLGVEND-UHFFFAOYSA-N 0.000 claims description 2
- KBMQWNZUFODTAD-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-5-(4-methylsulfanylphenyl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound C1=CC(SC)=CC=C1C1=C(C=2N=C(C)C=CC=2)N=C2N1CCN2 KBMQWNZUFODTAD-UHFFFAOYSA-N 0.000 claims description 2
- PAVUSSWRYIYZIA-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-5-[4-(trifluoromethyl)phenyl]-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=N1 PAVUSSWRYIYZIA-UHFFFAOYSA-N 0.000 claims description 2
- ZOWNKSFFMQGPLX-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-3,7-dihydro-2h-imidazo[1,2-a]imidazole-2-carbonitrile Chemical compound CC1=CC=CC(C2=C(N3CC(NC3=N2)C#N)C=2SC3=CC=NC=C3C=2)=N1 ZOWNKSFFMQGPLX-UHFFFAOYSA-N 0.000 claims description 2
- VZIYQUJFOYMKOF-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-3,7-dihydro-2h-imidazo[1,2-a]imidazole-2-carboxamide Chemical compound CC1=CC=CC(C2=C(N3CC(NC3=N2)C(N)=O)C=2SC3=CC=NC=C3C=2)=N1 VZIYQUJFOYMKOF-UHFFFAOYSA-N 0.000 claims description 2
- RQFQMDXCYDFWAR-UHFFFAOYSA-N 6-[2-(6-methylpyridin-2-yl)-1,5,6,7-tetrahydroimidazo[1,2-a]pyrimidin-3-yl]quinoline Chemical compound CC1=CC=CC(C2=C(N3CCCNC3=N2)C=2C=C3C=CC=NC3=CC=2)=N1 RQFQMDXCYDFWAR-UHFFFAOYSA-N 0.000 claims description 2
- WSFKXNUKPMUAKU-UHFFFAOYSA-N 7-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]-2-pyrazol-1-ylquinoxaline Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=C3N=C(C=NC3=CC=2)N2N=CC=C2)=N1 WSFKXNUKPMUAKU-UHFFFAOYSA-N 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- QUYROULMCXSYOP-UHFFFAOYSA-N [6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-3,7-dihydro-2h-imidazo[1,2-a]imidazol-2-yl]methanamine Chemical compound CC1=CC=CC(C2=C(N3CC(CN)NC3=N2)C=2SC3=CC=NC=C3C=2)=N1 QUYROULMCXSYOP-UHFFFAOYSA-N 0.000 claims description 2
- PLLQTHRWISRIJN-UHFFFAOYSA-N [6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-3,7-dihydro-2h-imidazo[1,2-a]imidazol-2-yl]methanol Chemical compound CC1=CC=CC(C2=C(N3CC(CO)NC3=N2)C=2SC3=CC=NC=C3C=2)=N1 PLLQTHRWISRIJN-UHFFFAOYSA-N 0.000 claims description 2
- BLTLTHLMCRGSGG-UHFFFAOYSA-N ethyl 6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-3,7-dihydro-2h-imidazo[1,2-a]imidazole-2-carboxylate Chemical compound N1C(C(=O)OCC)CN(C=2C=3SC4=CC=NC=C4C=3)C1=NC=2C1=CC=CC(C)=N1 BLTLTHLMCRGSGG-UHFFFAOYSA-N 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- IXPDJOHDCPXJJI-UHFFFAOYSA-N n,n-dimethyl-4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=C(C=2N=C(C)C=CC=2)N=C2N1CCN2 IXPDJOHDCPXJJI-UHFFFAOYSA-N 0.000 claims description 2
- FEJLXGUUVGKMCR-UHFFFAOYSA-N n-[4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=C(C=2N=C(C)C=CC=2)N=C2N1CCN2 FEJLXGUUVGKMCR-UHFFFAOYSA-N 0.000 claims description 2
- 201000008006 pharynx cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- SASIVFYMNRMNSM-UHFFFAOYSA-N 5-(3-fluoro-4-methoxyphenyl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound C1=C(F)C(OC)=CC=C1C1=C(C=2N=C(C)C=CC=2)N=C2N1CCN2 SASIVFYMNRMNSM-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- VLOVOCJPVSFPDG-UHFFFAOYSA-N ethyl 1-acetyl-6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydroimidazo[1,2-a]imidazole-2-carboxylate Chemical compound CC(=O)N1C(C(=O)OCC)CN(C=2C=3SC4=CC=NC=C4C=3)C1=NC=2C1=CC=CC(C)=N1 VLOVOCJPVSFPDG-UHFFFAOYSA-N 0.000 claims 1
- RTOKNYBZWRJMLL-UHFFFAOYSA-N n-[[6-(6-methylpyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-3,7-dihydro-2h-imidazo[1,2-a]imidazol-2-yl]methyl]acetamide Chemical compound N1C(CNC(=O)C)CN(C=2C=3SC4=CC=NC=C4C=3)C1=NC=2C1=CC=CC(C)=N1 RTOKNYBZWRJMLL-UHFFFAOYSA-N 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 abstract description 37
- 108091008036 Immune checkpoint proteins Proteins 0.000 abstract description 37
- 230000002401 inhibitory effect Effects 0.000 abstract description 25
- 230000004614 tumor growth Effects 0.000 abstract description 18
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 229940125904 compound 1 Drugs 0.000 description 147
- 241000699666 Mus <mouse, genus> Species 0.000 description 144
- 239000003981 vehicle Substances 0.000 description 89
- 238000012360 testing method Methods 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 70
- 229940079593 drug Drugs 0.000 description 66
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 61
- 229960003784 lenvatinib Drugs 0.000 description 60
- 150000003839 salts Chemical class 0.000 description 49
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 45
- 238000001647 drug administration Methods 0.000 description 42
- 238000007912 intraperitoneal administration Methods 0.000 description 41
- 238000010172 mouse model Methods 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 26
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 25
- 229940110808 lenvatinib 10 mg Drugs 0.000 description 24
- 238000002054 transplantation Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 230000037396 body weight Effects 0.000 description 18
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 16
- 239000012270 PD-1 inhibitor Substances 0.000 description 15
- 239000012668 PD-1-inhibitor Substances 0.000 description 15
- 229940121655 pd-1 inhibitor Drugs 0.000 description 15
- 206010041823 squamous cell carcinoma Diseases 0.000 description 15
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 14
- 230000008859 change Effects 0.000 description 14
- 208000009956 adenocarcinoma Diseases 0.000 description 12
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 11
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 206010015548 Euthanasia Diseases 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 7
- 239000012271 PD-L1 inhibitor Substances 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 210000003128 head Anatomy 0.000 description 7
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 7
- 229960002621 pembrolizumab Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 7
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 150000003852 triazoles Chemical class 0.000 description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000017572 squamous cell neoplasm Diseases 0.000 description 6
- AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 5
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 5
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 229960003301 nivolumab Drugs 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000007492 two-way ANOVA Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 101150051188 Adora2a gene Proteins 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 4
- SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000002698 KIR Receptors Human genes 0.000 description 3
- 108010043610 KIR Receptors Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000007452 Plasmacytoma Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 208000026037 malignant tumor of neck Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- 241000272194 Ciconiiformes Species 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 101150081330 MOC1 gene Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 101100041989 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sds23 gene Proteins 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 206010006007 bone sarcoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 229940055760 yervoy Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KFZWSKRSBVNDBY-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazole Chemical compound CC1=CC=CC(C=2NC3=NCCN3C=2C=2C=C3OCOC3=CC=2)=N1 KFZWSKRSBVNDBY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073086 Iris melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010073101 Mucinous breast carcinoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000018420 bone fibrosarcoma Diseases 0.000 description 1
- 201000007476 breast mucinous carcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000009636 cerebral lymphoma Diseases 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- UHYNYIGCGVDBTC-UHFFFAOYSA-N ethyl 1h-imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC=CN1 UHYNYIGCGVDBTC-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000008906 kidney fibrosarcoma Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 229940064847 lenvima Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 201000002350 malignant ciliary body melanoma Diseases 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- CSNVAYIBJSDFNW-UHFFFAOYSA-N n-[4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]phenyl]methanesulfonamide Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=CC(NS(C)(=O)=O)=CC=2)=N1 CSNVAYIBJSDFNW-UHFFFAOYSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940121597 pralsetinib Drugs 0.000 description 1
- GBLBJPZSROAGMF-BATDWUPUSA-N pralsetinib Chemical compound CO[C@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 GBLBJPZSROAGMF-BATDWUPUSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 229940121610 selpercatinib Drugs 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 229940121497 sintilimab Drugs 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZBPKFNWZTBSBOH-UHFFFAOYSA-N tert-butyl n-[4-[6-(6-methylpyridin-2-yl)-3,7-dihydro-2h-imidazo[1,2-a]imidazol-5-yl]phenyl]carbamate Chemical compound CC1=CC=CC(C2=C(N3CCNC3=N2)C=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=N1 ZBPKFNWZTBSBOH-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention is characterized in that a small molecule kinase inhibitor that blocks the TGF- ⁇ (transforming growth factor- ⁇ ) signal transduction pathway is administered in combination with at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor to prevent or treat tumors. It relates to a pharmaceutical composition for the treatment, a method for preventing or treating tumors, and a use of the pharmaceutical composition.
- TGF- ⁇ transforming growth factor- ⁇
- tumor cells By secreting a substance that makes T cells inactive, tumor cells evade immune cell attack, change the tumor microenvironment, divide rapidly, and can metastasize to other tissues beyond the tissue in which the tumor cell originated. characterized by it. On the other hand, tumor cells create blood vessels by themselves to obtain nutrients required for rapid growth and metastasis (Tumor angiogenesis).
- Regulatory T cells are known to be the main cells involved in immune evasion of tumor cells, and various treatment strategies have been developed to reduce the number of regulatory T cells in tumor tissues. For example, as a method of reducing the number of T cells, chemotherapy in which cyclophosphamide (CP) is administered at a low concentration to control the immunosuppressive response, and CD25 and CTLA- Methods using immune checkpoint modulators such as antibodies targeting molecules such as 4, PD-1 or chemokine receptors have been developed, and ipilimumab (Yervoy®) targeting CTLA-4 and PD-1 (Programmed cell death protein-1) targeting nivolumab (nivolumab, Opdivo TM ) and pembrolizumab (pembrolizumab, Keytruda®) have received marketing approval from the US Food and Drug Administration (FDA).
- CP cyclophosphamide
- CTLA-4 and PD-1 Programmed cell death protein-1
- FDA US Food and Drug Administration
- vascular endothelial growth factor receptor (VEGFR) 1 to 3 3
- PDGFR- ⁇ platelet-derived growth factor receptor
- RET transfection
- the FDA approved the combination of the receptor tyrosine kinase inhibitor lenvatinib (Lenvatinib, Lenvima®) and the anti-PD-1 antibody pembrolizumab for the treatment of advanced renal cancer and advanced endometrial cancer. .
- Patent Document 1 Korean Patent Registration No. 2220275
- the present inventors administer a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway to a subject in combination with at least one selected from immune checkpoint regulators and receptor tyrosine kinase inhibitors, the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, The present invention was completed by confirming that the inhibitor of receptor tyrosine kinase or the immune checkpoint modulator was more effective in inhibiting tumor growth than the case of administration alone and was safe.
- the present invention is a pharmaceutical composition for preventing or treating tumors, comprising a small molecule kinase inhibitor that blocks the TGF- ⁇ signal transduction pathway, comprising a small molecule that blocks the TGF- ⁇ signal transduction pathway
- a pharmaceutical composition wherein the kinase inhibitor is administered in combination with at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor.
- small molecule kinase inhibitors that block the TGF- ⁇ signaling pathway; And it provides a pharmaceutical composition for preventing or treating tumors, comprising at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor.
- the invention provides a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway; and at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor.
- the invention provides a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway; and administering to the subject at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor.
- the invention is a use of a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, administered in combination with at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor, to prevent or treat tumors. It provides a use for preparing a medicament for
- the invention provides a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway; and instructions for administering a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway in combination with at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor. do.
- a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway is administered to a subject in combination with at least one selected from immune checkpoint modulators and receptor tyrosine kinase inhibitors
- the small molecule kinase inhibitor, immune checkpoint modulator, or tyrosine kinase inhibitor is used alone. It is more effective in inhibiting tumor growth than when
- Figure 1 shows the inhibitory effect of increasing tumor volume in a melanoma mouse model with combined administration of Compound 1 and anti-PD-1 antibody, control (vehicle), administration of Compound 1 alone, and administration of anti-PD-1 antibody alone. .
- Figure 2 shows the change in body weight during the test period of the control (vehicle) and test drug-administered groups (Compound 1 + anti-PD-1 antibody, Compound 1, anti-PD-1 antibody) in a melanoma mouse model.
- Figure 3 shows a control group (vehicle + anti-IgG2b antibody) and a test drug administration group (vehicle + anti-PD-L1 antibody, compound 1 15 mg / kg / day + anti-PD-L1 antibody, compound 1 30 in a melanoma mouse model) mg/kg/day + anti-PD-L1 antibody, LY2157299 75 mg/kg/day + anti-PD-L1 antibody and LY2157299 150 mg/kg/day + anti-PD-L1 antibody) as mean ⁇ SEM is indicated by
- FIG. 4 shows a control group (vehicle + anti-IgG2b antibody) and a test drug administration group (vehicle + anti-PD-L1 antibody, compound 1 15 mg / kg / day + anti-PD-L1 antibody, compound 1 30 in a melanoma mouse model) mg/kg/day + anti-PD-L1 antibody, LY2157299 75 mg/kg/day + anti-PD-L1 antibody and LY2157299 150 mg/kg/day + anti-PD-L1 antibody) 22 days from the date of cell line inoculation It shows the tumor volume at the time of becoming.
- Figure 5 is a control group (vehicle + anti-IgG2b antibody) and a test drug administration group (vehicle + anti-PD-L1 antibody, compound 1 15 mg / kg / day + anti-PD-L1 antibody, compound 1 30 in a melanoma mouse model) mg/kg/day + anti-PD-L1 antibody, LY2157299 75 mg/kg/day + anti-PD-L1 antibody and LY2157299 150 mg/kg/day + anti-PD-L1 antibody) during the test period is shown.
- Figure 6 shows the inhibitory effect of tumor volume increase and drug administration 15 in a melanoma mouse model in combination administration of Compound 1 and anti-CTLA-4 antibody, control group (vehicle), administration of Compound 1 alone, and administration of anti-CTLA-4 antibody alone 15 It shows the difference in tumor volume measured on the 1st day.
- Figure 7 shows the change in body weight during the test period of the control group (vehicle), compound 1 alone administration group, anti-CTLA-4 antibody alone administration group, and compound 1 and anti-CTLA-4 antibody combination administration group in a melanoma mouse model. .
- Figure 8 shows the tumor volume increase inhibitory effect and drug administration date of compound 1 and anti-PD-1 antibody combination administration, control group (vehicle), compound 1 administration alone, and anti-PD-1 antibody administration alone in a colorectal cancer mouse model. It shows the difference in tumor weight measured on the 26th day from.
- Figure 9 shows the tumor volume increase inhibitory effect and drug administration date of compound 1 and anti-CTLA-4 antibody combination administration, control group (vehicle), compound 1 administration alone, and anti-CTLA-4 antibody administration alone in a mouse model of colorectal cancer. It shows the difference in tumor volume measured on the 26th day from .
- Figure 11 shows compound 1 and lenvatinib combination administration, compound 1, lenvatinib, and anti-PD-1 antibody combination administration, control group (vehicle), lenvatinib alone administration, anti-PD-1 in a mouse model of colorectal cancer It shows the effect of inhibiting the increase in tumor volume when the antibody is administered alone, when the combination of lenvatinib and anti-PD-1 antibody is administered, and when Compound 1 is administered alone.
- control (vehicle) and test drug administration groups (anti-CTLA-4 antibody, lenvatinib, lenvatinib + anti-PD1 antibody, lenvatinib + anti-CTLA-4 antibody, compound 1 in a mouse model of colorectal cancer) , Compound 1 + anti-CTLA-4 antibody, and Compound 1 + lenvatinib + anti-CTLA-4 antibody) during the test period.
- Figure 13 is a control group (vehicle) and test drug administration groups (compound 1, lenvatinib, anti-CTLA-4 antibody, anti-PD1 antibody, compound 1 + anti-CTLA-4 antibody, compound 1 + anti-CTLA-4 antibody, compound 1 + anti-CTLA-4 antibody) in a mouse model of colorectal cancer.
- test drug administration groups compound 1, lenvatinib, anti-CTLA-4 antibody, anti-PD1 antibody, compound 1 + anti-CTLA-4 antibody, compound 1 + anti-CTLA-4 antibody, compound 1 + anti-CTLA-4 antibody
- FIG. 14 shows the inhibitory effect of tumor volume increase in the combination administration of Compound 1 and anti-PD-1 antibody, the control group (vehicle), the administration of Compound 1 alone, and the administration of anti-PD-1 antibody alone in a sarcoma mouse model.
- FIG. 15 shows tumor remission rates in a sarcoma mouse model with combination administration of Compound 1 and anti-CTLA-4 antibody, control (vehicle), administration of Compound 1 alone, and administration of anti-CTLA-4 antibody alone.
- 16 shows a control group (vehicle) and a test drug administration group (anti-PD-1 antibody, compound 1, anti-CTLA-4 antibody, compound 1+ anti-PD-1 antibody and compound 1+anti-CTLA-4 antibody in a sarcoma mouse model). 4 antibody) shows the change in body weight during the test period.
- Figure 17 shows the tumor volume increase inhibitory effect and cell line inoculation date of combination administration of Compound 1 and anti-PD-1 antibody, control group (vehicle), Compound 1 administration alone, and anti-PD-1 antibody administration alone in a breast cancer mouse model. It shows the difference in tumor volume measured on the 23rd day from
- Figure 18 shows the tumor volume increase inhibitory effect and cell line inoculation date of compound 1 and anti-CTLA-4 antibody combination administration, control group (vehicle), compound 1 administration alone, and anti-CTLA-4 antibody administration alone in breast cancer mouse model It shows the difference in tumor volume measured on the 23rd day.
- FIG. 19 shows a control group (vehicle) and a test drug administration group (anti-PD-1 antibody, compound 1, anti-CTLA-4 antibody, compound 1+ anti-PD-1 antibody, and compound 1+ anti-CTLA in a mouse model of breast cancer).
- -4 antibody shows the change in body weight during the test period.
- FIG. 20 shows the survival rate of mice in the case of combination administration of Compound 1 and anti-PD-1 antibody, control, administration of Compound 1 alone, and administration of anti-PD-1 antibody alone in a mouse model of bladder carcinoma.
- Figure 21 shows the change in body weight during the test period of the control group and the test drug administration group (Compound 1, anti-PD-1 antibody, and Compound 1+ anti-PD-1 antibody) in a bladder carcinoma mouse model.
- One aspect of the present invention is a pharmaceutical composition for preventing or treating tumors comprising a small molecule kinase inhibitor that blocks the TGF- ⁇ (transforming growth factor- ⁇ ) signal transduction pathway, comprising a small molecule that blocks the TGF- ⁇ signal transduction pathway
- a pharmaceutical composition wherein the kinase is administered in combination with at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor.
- the "small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway” includes a TGF- ⁇ type I receptor kinase inhibitor, a kinase inhibitor that double inhibits TGF- ⁇ type I receptor and Vascular Endothelial Growth Factor Receptor (VEGFR)-2, etc.
- VEGFR Vascular Endothelial Growth Factor Receptor
- the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway is a novel 2-pyridyl-substituted imidazole derivative disclosed in Korean Patent Registration No. 1938368 or a pharmaceutically acceptable salt or solvate thereof.
- the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway is 1-[6-(6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-2,3-dihydro -imidazo[1,2-a]imidazol-1-yl]-ethanone, 6-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[ 1,2-a]imidazol-3-yl]-quinoxaline, 6-[2-(6-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-imidazo[1, 2-a]pyrimidin-3-yl]-quinoxaline, 6-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[1,2-a] Imidazol-3-yl]-quinoline, 6-[2-(6-methyl-pyridin-2-yl)-5,6,7,8
- the term "pharmaceutically acceptable salt” refers to salts suitable for use in contact with human and animal tissues.
- suitable salts with such inorganic and organic acids include, but are not limited to, acetic acid, citric acid, formic acid, fumaric acid, hydrochloric acid, lactic acid, maleic acid, malic acid, methane-sulfonic acid, nitric acid, phosphoric acid, p-toluenesulfonic acid, succinic acid , sulfuric acid, sulfuric acid, tartaric acid, trifluoroacetic acid and the like.
- the pharmaceutically acceptable salts are inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and mono-, di-, trialkyl and aryl amines. It may be a pharmaceutically acceptable acid- or base-addition salt formed by reaction with organic bases such as aryl amines and substituted ethanolamines.
- the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway is 6-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo [1,2-a]imidazol-3-yl]-quinoxaline, 6-[2-(6-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-imidazo[1 ,2-a]pyrimidin-3-yl]-quinoxaline, 6-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[1,2-a ]imidazol-3-yl]-quinoline, 2-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3 -yl]-thieno[3,2-c]pyridine, 6-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro
- TGF- ⁇ inhibits cell proliferation and induces apoptosis in a normal environment, but exists in high concentrations in a tumor microenvironment, suppresses immunity, promotes cancer cell metastasis, and induces fibrosis and vascularization of cancer stroma. It is known to increase the density and hardness of tumors through the promotion of angiogenesis and to block the delivery of anticancer drugs and immune cell infiltration into tumor tissues, resulting in drug resistance.
- the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway not only inhibits cancer cell immune evasion and cancer cell metastasis, but also inhibits TGF- ⁇ -induced fibrosis of the tumor matrix and normalizes tumor vascular function by
- the intratumoral delivery of drugs used in combination and tumor infiltration of immune cells can be increased, and the oxygen concentration of the microenvironment around the tumor can also be increased.
- the small molecule kinase inhibitors that block the TGF- ⁇ signaling pathway of the present invention are immune checkpoint modulators (e.g., drugs that suppress regulatory T cells by inhibiting immune checkpoint proteins, effector T cells by binding to immune checkpoint proteins).
- the small molecule kinase inhibitor blocking the TGF- ⁇ signal transduction pathway of the present invention is used in combination with an immune checkpoint modulator, improved anticancer efficacy can be exhibited by increasing the tumor infiltration rate of immune cells, which are targets of the immune checkpoint modulator.
- the small molecule kinase inhibitor blocking the TGF- ⁇ signal transduction pathway of the present invention is used in combination with chemotherapy, targeted therapeutics, or nanoparticles, it is possible to exhibit improved anticancer efficacy by increasing the drug delivery efficiency.
- a small molecule kinase inhibitor that blocks the TGF- ⁇ signal transduction pathway is used in combination with radiation therapy, an improved tumor treatment/inhibition effect can be exhibited by increasing the oxygen concentration in the tumor microenvironment.
- Immune checkpoint refers to a group of signaling molecules possessed by immune cells, which can regulate and control the continuity of the immune response while maintaining self-tolerance, and an inhibitory pathway that maintains self-tolerance and helps the immune response. It consists of signaling molecules involved in stimulation and signaling molecules involved in stimulation pathways. In addition, the effectiveness of the immune response is determined by the delicate balance between co-stimulatory and co-inhibitory signals.
- An immune checkpoint protein refers to both a protein involved in a pathway that suppresses an immune response and a protein involved in a pathway that activates an immune response.
- the immune checkpoint protein is a protein involved in a signaling pathway that inhibits the activity of regulatory T cells or a signaling pathway that directly stimulates effector T cells or memory T cells. It may be a protein involved in
- immune checkpoint regulation may inhibit immune tolerance or activate the immune system, inhibit all signaling pathways that activate regulatory T cells involved in immune tolerance, or effector T cells or memory to increase antitumor immune responses. stimulating signaling pathways that activate T cells.
- an immune checkpoint protein there is a T cell receptor, and as the T cell receptor protein, programmed cell death protein ligand 1 (PD-L1), programmed cell death protein (programmed cell death protein 1) : PD-1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), B and T lymphocyte attenuator (BTLA), killer cell immunoglobulin -Killer cell immunoglobulin-like receptor (KIR), lymphocyte activation gene 3 (LAG3), T cell membrane protein 3 (corresponding to T-cell immunoglobulin mucin receptor 3): TIM3 ), OX40, VISTA (V-domain immunoglobuin suppressor of T cell activation), TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domain), 4-1BB (CD137), GITR (Glucocorticoid-induced tumor necrosis factor related protein) and adenosine A2a There are receptors (adenosine A2a receptor: A2aR), etc.,
- the immune checkpoint modulator is an anti-immune checkpoint protein antibody or an antigen-binding fragment thereof, an aptamer, a fusion protein that binds to an immune checkpoint protein, or a small molecule compound that binds to an immune checkpoint protein or is involved in a mechanism related to inhibition or activation thereof.
- the immune checkpoint modulator is an immune checkpoint protein selected from the group consisting of PD-L1, PD-1, CTLA-4, BTLA, KIR, LAG3, TIM3, OX40, VISTA, TIGIT, 4-1BB, GITR and A2aR It may be a substance that modulates an involved signal transduction pathway.
- the immune checkpoint modulator is a receptor of a T cell selected from the group consisting of PD-L1, PD-1, CTLA-4, BTLA, KIR, LAG3, TIM3, OX40, VISTA, TIGIT, 4-1BB, GITR and A2aR It may be a substance that inhibits signal transduction or reduces expression.
- the immune checkpoint modulator inhibits signal transduction by PD-L1, PD-1, CTLA-4, BTLA, KIR, LAG3, TIM3, OX40, VISTA, TIGIT, 4-1BB, GITR, A2aR, or a combination thereof or suppress expression of regulatory T cells or activate effector T cells or memory T-cells.
- the immune checkpoint modulator may be a PD-L1 inhibitor, a PD-1 inhibitor, a CTLA-4 inhibitor, an OX40 agonist, or a combination thereof.
- the immune checkpoint modulator is at least one selected from the group consisting of aptamers, peptides, antibodies, and antigen-binding fragments of the antibodies that specifically bind to the PD-L1 protein; at least one selected from the group consisting of aptamers, peptides, antibodies, and antigen-binding fragments of the antibodies that specifically bind to the PD-1 protein; At least one selected from the group consisting of aptamers, peptides, antibodies, and antigen-binding fragments of the antibodies that specifically bind to the OX40 protein; And it may be at least one selected from at least one selected from aptamers, peptides, antibodies, and antigen-binding fragments of the antibodies that specifically bind to the CTLA-4 protein.
- the immune checkpoint modulator is an anti-PD-L1 antibody or antigen-binding fragment thereof; anti-PD-1 antibody or antigen-binding fragment thereof; anti-OX40 antibody or antigen-binding fragment thereof or anti-CTLA-4 antibody or antigen-binding fragment thereof.
- a PD-L1 inhibitor may be a neutralizing antibody or antigen-binding fragment thereof that binds to PD-L1, an aptamer or a fusion protein comprising an antibody capable of binding to PD-L1, or a small molecule compound that inhibits the function of PD-L1.
- PD-L1 inhibitors include, but are not limited to, BMS-936559 (MDX1105, Bristol Myers Squibb), MEDI4736 (MedImmune, AstraZeneca), MPDL3280A (Roche), CK-301 (Checkpoint Therapeutica), and MSB0010718C (Merck). .
- a PD-1 inhibitor may be a neutralizing antibody or antigen-binding fragment thereof that binds to PD-1, an aptamer or a fusion protein comprising an antibody capable of binding to PD-1, or a small molecule compound that inhibits the function of PD-1. may, but is not limited thereto.
- Examples of PD-1 inhibitors include AMP-224 (Amplimmune, GlaxoSmith Klein), AMP-514 (MEDI0680, Amplimmune, GlaxoSmith Klein), nivolumab (Opdivo, Bristol Myers Squibb), pembrolizumab (Pembrolizumab, Keytruda, Merck).
- Pidilizumab (Pidilizumab, Cure Tech), BGB-A317 (BeiGene, Celgene), PF-06801591 (Pfizer), PDR001 (Novartis), TSR-042 (Tesaro, GlaxoSmithKline), MGA012 (Incyte/MacroGenics), IBI308 (Innovent, Eli Lilly), and BI 754091 (Boehringer Ingelheim), but are not limited thereto.
- the CTLA-4 inhibitor may be a neutralizing antibody or antigen-binding fragment thereof that binds to CTLA-4, an aptamer or a fusion protein comprising an antibody capable of binding to CTLA-4, or a small molecule compound that inhibits the function of CTLA-4. may, but is not limited thereto.
- CTLA-4 inhibitors include, but are not limited to, ipilimumab (Yervoy, Bristol Myers Squibb) and tremelimumab (Pfizer).
- the OX40 agonist may be, but is not limited to, a neutralizing antibody or antigen-binding fragment thereof that binds to OX40, an aptamer or a fusion protein comprising an antibody capable of binding to OX40, or a small molecule compound that activates the function of OX40.
- OX40 agonists include ABBV-368 (Abbvie), GSK3174998 (GlaxoSmithKline), MOXR0916 (Genentech), INCAGN01949 (Incyte Biosciences International), IBI101 (Innovent), BMS-986178 (Bristol Myers Squibb), PF-04518600 (Pfizer), and the like. There is, but is not limited to this.
- receptor tyrosine kinase refers to a transmembrane protein that penetrates cell membranes, and refers to receptors responsible for cell signaling pathways that regulate cell proliferation, cell migration, cell cycle, and cell differentiation.
- receptor tyrosine kinase inhibitor in the present invention refers to an anti-receptor tyrosine kinase antibody or antigen-binding fragment thereof, an aptamer, a fusion protein that binds to a receptor tyrosine kinase protein, or a mechanism involved in binding to or inhibiting a receptor tyrosine kinase protein.
- the receptor tyrosine kinase inhibitor may be an inhibitor of one or more tyrosine kinases selected from VEGF receptors, FGF receptors, PDGFR ⁇ , KIT, RET, and c-Met.
- the receptor tyrosine kinase inhibitor is an antibody that binds to one or more tyrosine kinases selected from VEGF receptors, FGF receptors, PDGFR ⁇ , KIT, RET, and c-Met, or antigen-binding fragments thereof, aptamers, or the tyrosine It may be a fusion protein comprising an antibody capable of binding to kinase, or a small molecule compound that selectively inhibits the tyrosine kinase.
- the receptor tyrosine kinase inhibitor is a compound that inhibits the function of one or more tyrosine kinases selected from VEGF receptors, FGF receptors, PDGFR ⁇ , KIT, RET and c-Met, or specifically binds to the tyrosine kinase protein It may be one or more selected from aptamers, peptides, antibodies, and antigen-binding fragments of the antibodies, cabozantinib, lenvatinib, vandetanib, selpercatinib, and pralsetinib and the like, but are not limited thereto.
- antibody may be a neutralizing antibody having the ability to neutralize a target protein.
- composition encompasses a product comprising the specified ingredients in predetermined amounts or proportions, as well as any product that results, directly or indirectly, from combining the specified ingredients in the specified amounts.
- pharmaceutical composition is from any carrier comprising at least one active ingredient and an inactive ingredient, as well as directly or indirectly from combination, complexation or aggregation of any two or more ingredients, or from decomposition of one or more ingredients, or It encompasses any product resulting from the interaction of one or more components or other type of reaction.
- tumor refers to a cellular disorder characterized by uncontrolled or unregulated cell proliferation, reduced cell differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at an ectopic site. refers to
- tumors include, but are not limited to, solid tumors and blood-borne tumors, and further include diseases of the skin, tissues, organs, bones, cartilage, blood, and blood vessels, or primary and metastatic tumors. do.
- the tumor can be (1) acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, such as myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythrocytic leukemia, myelodysplastic syndrome, preleukemia and chronic leukemias including but not limited to myelomonocytic leukemia (CMML), (2) chronic leukemias including but not limited to chronic myelocytic (granular) leukemia, chronic lymphocytic leukemia and hairy cell leukemia; (3) lymphoma, including but not limited to Hodgkin's disease and non-Hodgkin's disease; (4) multiple myeloma, including but not limited to asymptomatic multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasma
- the tumor may be a metastatic tumor, an unresectable tumor, or a locally advanced tumor.
- the tumor is melanoma, sarcoma, brain tumor, breast cancer, adrenal cancer, thyroid cancer, pancreatic cancer, pituitary cancer, glioblastoma, eye cancer, vaginal cancer, vulvar cancer, cervical cancer, endometrial carcinoma, uterine cancer, ovarian cancer, esophageal cancer, stomach cancer , colon cancer, rectal cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, lung cancer, testicular cancer, prostate cancer, penile cancer, oral cancer, basal cancer, salivary gland cancer, pharynx cancer, skin cancer, kidney cancer, Wilms' tumor, bladder cancer, head and neck cancer, head and neck squamous cell It may be selected from the group consisting of cancer, hepatocellular carcinoma, appendix cancer, bronchial cancer, choriocarcinoma, chordoma, ependymoma, gastrointestinal stromal tumor (GIST), neuroendocrine cancer and urethral
- prevention refers to any action that inhibits cancer or delays the onset of cancer
- treatment refers to any action that improves or beneficially alters the symptoms of cancer.
- the term “subject” refers to an animal, preferably a mammal and most preferably a human.
- a subject in need of treatment of a tumor or inhibition of tumor growth may be, but is not limited to, a subject at risk of developing or experiencing a tumor recurrence.
- a subject in need of tumor treatment or tumor growth inhibition may be a subject who has been treated with one or more anti-cancer therapies selected from surgery, radiation, and chemotherapy, but is not limited thereto.
- a subject in need of tumor treatment or tumor growth inhibition may be a subject who has received at least one chemotherapy selected from the group consisting of a receptor tyrosine kinase inhibitor and an immune checkpoint modulator.
- combination means a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway simultaneously with an immune checkpoint modulator and/or receptor tyrosine kinase inhibitor in combination therewith. or individually administered at different time points.
- the small molecule kinase inhibitors, immune checkpoint modulators, and/or receptor tyrosine kinase inhibitors that block the TGF- ⁇ signaling pathway are administered individually, their administration cycles may differ from each other, and administration routes may also differ from each other.
- the term "pharmaceutically acceptable” refers to a substance that is not biological or otherwise undesirable, i.e., causes any undesirable biological effect or interacts in a detrimental manner with any other component of the pharmaceutical composition in which it is included. means a substance that can be administered to a subject together with the composition, but not otherwise.
- pharmaceutically acceptable carrier refers to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ingredients of the formulation.
- examples of pharmaceutically acceptable carriers include, but are not limited to, saline, Ringer's solution and dextrose solution.
- the carrier will of course be chosen to minimize any degradation of the active ingredient and to minimize any adverse side effects to the subject, as is well known to those skilled in the art.
- the pH of the solution is preferably from about 5 to about 8, more preferably from about 7 to about 7.5.
- the carrier may be capable of sustained release, such as semipermeable matrices of solid hydrophobic polymers comprising the antibody, the matrix of which is in the form of shaped articles, eg films, liposomes or microparticles. contains the product. It will be apparent to those skilled in the art that certain carriers will be more preferable depending on, for example, the route of administration and the concentration of the composition being administered. Additionally, pharmaceutically acceptable carriers are known to those skilled in the art and many of these will be standard carriers for administering drugs to humans, typically including solutions such as sterile water, saline and buffer solutions at physiological pH.
- the pharmaceutical composition of the present invention may include thickeners, diluents, buffers, preservatives, surface active agents, and the like. .
- compositions for parenteral injection include pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions immediately prior to use.
- suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles are water, ethanol, glycerol, polyols (such as propylene glycol, polyethylene glycol, etc.), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and ethyl.
- Injectable organic esters such as oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions may also contain preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of microbial action can be ensured by the inclusion of various antibacterial and antifungal agents such as parabens, chlorobutanol, phenolsorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
- Injectable depot forms are made by forming microencapsule matrices of the drug with biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending on the ratio of drug to polymer and the nature of the particular polymer used, the rate of drug release can be controlled. Injectable depot formulations are also prepared by entrapping the drug into liposomes or microemulsions suitable for body tissue. Injectable formulations may contain, for example, a sterilizing agent in the form of a sterile solid composition which can be dissolved or dispersed in sterile water or other sterile injectable media immediately prior to use, such as by filtration through a bacterial retaining filter. It can be sterilized by including.
- biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides).
- the rate of drug release can be controlled.
- Injectable depot formulations are also prepared
- compositions for oral administration may be in the form of, for example, tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups or elixirs.
- An orally administered pharmaceutical composition may contain one or more optional agents, for example, a sweetening agent such as fructose, aspartame or saccharin; A flavoring agent such as peppermint, oil of wintergreen or cherry colorant and a preservative may be included to render the pharmaceutically palatable preparation.
- the composition may be coated to retard disintegration and absorption in the gastrointestinal tract, thereby providing sustained action over an extended period of time.
- a selectively permeable membrane surrounding an osmotically active driving compound is also suitable for orally administered compounds of the present invention.
- fluid from the environment surrounding the capsule is absorbed by the propellant compound and expands to displace the agent or agent composition through the opening.
- These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profile of an immediate release formulation.
- Substances that delay release time such as glycerol monostearate or glycerol stearate may also be used.
- Oral compositions may include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Such vehicles are preferably of pharmaceutical grade.
- compositions for oral liquids for example suspensions, elixirs and solutions, preparations such as suitable carriers, excipients or diluents may contain water, saline, alkylene glycols (eg propylene glycol), polyalkylene glycols (eg For example, polyethylene glycol) oil, alcohol, a weakly acidic buffer between pH 4 and pH 6 (eg, between about 5.0 mM and about 50.0 mM acetate, citrate, ascorbate), and the like.
- a weakly acidic buffer between pH 4 and pH 6 eg, between about 5.0 mM and about 50.0 mM acetate, citrate, ascorbate
- flavoring agents, preservatives, colorants, bile salts, acylcarnitines, and the like may be added.
- the pharmaceutical composition for oral administration may take the form of a tablet, capsule, etc. formulated in a conventional manner.
- a therapeutically effective amount of a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway refers to more than the minimum dosage of the small molecule kinase inhibitor disclosed herein necessary to achieve a desired therapeutic effect, and is associated with tumor symptoms, tumor dosages sufficient to reduce growth and the like.
- therapeutically effective amounts of immune checkpoint modulators and receptor tyrosine kinase inhibitors refer to at least the minimal dosage of the immune checkpoint modulators and receptor tyrosine kinase inhibitors disclosed herein necessary to achieve the desired therapeutic effect, tumor symptoms, tumor growth, etc.
- the effectiveness of one or more combinations selected from small molecule kinase inhibitors disclosed herein with immune checkpoint modulators and receptor tyrosine kinase inhibitors in treating tumors is based on one or more clinical symptoms, and/or physiological markers associated with the condition. It can be determined by observing improvement in the subject. Improvement of the tumor may also be indicated by a reduced need for concomitant treatment.
- the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway may be administered once, twice, or three times or more per day, but is not limited thereto.
- the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway may be administered twice a day at the same dose or different doses. More preferably, the small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway may be administered twice a day at the same dose.
- the small molecule kinase inhibitor, immune checkpoint modulator and receptor tyrosine kinase inhibitor are each independently administered topically, parenterally, orally, intravenously, intramuscularly. It may be administered to a subject in need of treatment through intramuscularly, subcutaneously, or aerosol administration, but is not limited thereto.
- a small molecule kinase inhibitor of the invention that blocks the TGF- ⁇ signaling pathway may be administered in combination with an immune checkpoint modulator.
- a small molecule kinase inhibitor of the invention that blocks the TGF- ⁇ signaling pathway may be administered in combination with a receptor tyrosine kinase inhibitor.
- a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway may be administered in combination with a receptor tyrosine kinase inhibitor and an immune checkpoint modulator.
- the small molecule kinase inhibitor, immune checkpoint modulator, and receptor tyrosine kinase inhibitor that block the TGF- ⁇ signaling pathway are contained as active ingredients in different formulations and administered simultaneously or at different times.
- small molecule kinase inhibitors, immune checkpoint modulators, and receptor tyrosine kinase inhibitors that block the TGF- ⁇ signaling pathway may be administered separately at different times.
- the small molecule kinase inhibitor may be administered orally.
- the immune checkpoint modulator and receptor tyrosine kinase inhibitor may be administered according to an administration method, dosage and administration cycle known in the art to which the present invention pertains.
- the present invention provides a pharmaceutical drug for the treatment of tumors comprising a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, for the treatment of tumor patients administered with an immune checkpoint modulator and/or a receptor tyrosine kinase inhibitor.
- a pharmaceutical drug for the treatment of tumors comprising a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, for the treatment of tumor patients administered with an immune checkpoint modulator and/or a receptor tyrosine kinase inhibitor.
- the invention includes small molecule kinase inhibitors that block the TGF- ⁇ signaling pathway, wherein the small molecule kinase inhibitors that block the TGF- ⁇ signaling pathway are immune checkpoint modulators and receptor tyrosine kinase inhibitors.
- Pharmacology for the treatment of tumors that enhances the action of an immune checkpoint regulator and/or receptor tyrosine kinase inhibitor or enhances the action of a small molecule kinase inhibitor that blocks the TGF- ⁇ signal transduction pathway by being administered in combination with one or more selected species. may be a composition.
- the invention provides a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway; And it may be a combination or pharmaceutical composition for preventing or treating tumors, comprising at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor.
- a small molecule kinase inhibitor, an immune checkpoint regulator, and a receptor tyrosine kinase inhibitor that block the TGF- ⁇ signaling pathway may be administered simultaneously, sequentially or separately, and a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, Types of immune checkpoint modulators and receptor tyrosine kinase inhibitors, types of tumors, administration methods and doses are as defined above.
- the term “combination” means a product resulting from the mixing or blending of two or more active ingredients, and includes both fixed and non-fixed combinations of the active ingredients.
- the term “fixed combination” means an active ingredient, such as a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, and one or more selected from immune checkpoint modulators and receptor tyrosine kinase inhibitors, all in the form of a single entity or dosage to a patient. means to be administered simultaneously.
- non-fixed combination refers to the active ingredient, such as a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, and one or more selected from immune checkpoint modulators and receptor tyrosine kinase inhibitors, in a subject separately. It is meant to be administered simultaneously, simultaneously or sequentially or separately without specific time limits, wherein such administration provides therapeutically effective levels of the two or more active ingredients in the body of the patient. Non-fixed combinations also apply to cocktail therapy, such as the administration of three or more active ingredients.
- the pharmaceutical composition or combination of the invention is 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a ]imidazol-5-yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, including melanoma, colon cancer, bladder cancer, sarcoma, breast cancer,
- a pharmaceutical composition or combination for preventing or treating cervical cancer, head and neck squamous cell carcinoma or liver cancer, which is administered in combination with a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) can be administered in combination with a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof)
- the pharmaceutical composition or combination of the invention is 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a
- a pharmaceutical composition or combination for preventing or treating melanoma comprising ]imidazol-5-yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof
- it may be a pharmaceutical composition or combination administered in combination with a PD-L1 inhibitor (preferably an anti-PD-L1 antibody or fragment thereof).
- the pharmaceutical composition or combination of the present invention comprises 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a ]imidazol-5-yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, including melanoma, colon cancer, sarcoma, breast cancer, cervical cancer , a pharmaceutical composition or combination for preventing or treating head and neck squamous cell carcinoma or liver cancer, which is administered in combination with a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof).
- a CTLA-4 inhibitor preferably an anti-CTLA-4 antibody or fragment thereof.
- the pharmaceutical composition or combination of the present invention comprises 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2- a]imidazol-5-yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, including colorectal cancer, cervical cancer, squamous cell carcinoma of the head and neck, or As a pharmaceutical composition for preventing or treating liver cancer, it may be a pharmaceutical composition or combination administered in combination with lenvatinib.
- the pharmaceutical composition or combination of the invention is 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a Colorectal cancer, cervical cancer, head and neck squamous cell carcinoma or liver cancer, including ]imidazol-5-yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof
- a pharmaceutical composition or combination for preventing or treating it may be a pharmaceutical composition or combination administered in combination with lenvatinib and a PD-1 inhibitor (preferably, an anti-PD-1 antibody or fragment thereof).
- the pharmaceutical composition or combination of the present invention comprises 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a ]imidazol-5-yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, including colorectal cancer, cervical cancer, head and neck squamous cell carcinoma or liver cancer
- a pharmaceutical composition or combination for preventing or treating it may be a pharmaceutical composition or combination administered in combination with lenvatinib and a CTLA-4 inhibitor (preferably, an anti-CTLA-4 antibody or fragment thereof).
- the pharmaceutical composition or combination of the invention is 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a Colorectal cancer, cervical cancer, head and neck squamous cell carcinoma or liver cancer, including ]imidazol-5-yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof
- a PD-1 inhibitor preferably, an anti-PD-1 antibody or fragment thereof
- a CTLA-4 inhibitor preferably, an anti-CTLA-4 antibody or fragment thereof
- a pharmaceutical composition or combination for preventing or treating may be a pharmaceutical composition or combination administered in combination with.
- the invention provides a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway; and administering at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor to the subject.
- a small molecule kinase inhibitor, an immune checkpoint regulator, and a receptor tyrosine kinase inhibitor that block the TGF- ⁇ signaling pathway may be administered simultaneously, sequentially or separately, and a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, Types of immune checkpoint modulators and receptor tyrosine kinase inhibitors, types of tumors, administration methods and doses are as defined above.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- 1) -[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof and a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) are administered to a subject.
- a PD-1 inhibitor preferably an anti-PD-1 antibody or fragment thereof
- It may be a method for preventing or treating melanoma, colorectal cancer, bladder cancer, sarcoma, breast cancer, cervical cancer, head and neck squamous cell carcinoma, or liver cancer in a subject comprising the step of administering.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- 1) -[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof and a PD-L1 inhibitor (preferably an anti-PD-L1 antibody or fragment thereof) are administered to a subject. It may be a method for preventing or treating melanoma in a subject comprising the step of administering.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- 1) -[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof and a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof) are administered to a subject
- a CTLA-4 inhibitor preferably an anti-CTLA-4 antibody or fragment thereof
- It may be a method for preventing or treating melanoma, colorectal cancer, sarcoma, breast cancer, cervical cancer, head and neck squamous cell carcinoma, or liver cancer in a subject comprising the step of administering.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5 -day) - [1,2,4] triazole [1,5-a] pyridine or a pharmaceutically acceptable salt thereof and lenvatinib to the subject comprising the step of administering to the subject colorectal cancer, cervical cancer, It may be a method for preventing or treating head and neck squamous cell carcinoma or liver cancer.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- 1)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, lenvatinib and a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) ) may be a method for preventing or treating colon cancer, cervical cancer, head and neck squamous cell carcinoma, or liver cancer in a subject comprising administering to the subject.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- 1)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, lenvatinib and a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof) ) may be a method for preventing or treating colon cancer, cervical cancer, head and neck squamous cell carcinoma, or liver cancer in a subject comprising administering to the subject.
- a CTLA-4 inhibitor preferably an anti-CTLA-4 antibody or fragment thereof
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- 1)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) and CTLA It may be a method for preventing or treating colorectal cancer, cervical cancer, head and neck squamous cell carcinoma or liver cancer in a subject comprising administering a -4 inhibitor (preferably, an anti-CTLA-4 antibody or fragment thereof) to the subject. .
- the present invention is the use of a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway administered in combination with at least one of an immune checkpoint modulator and a receptor tyrosine kinase inhibitor to prevent tumors. It relates to use for the manufacture of a medicament for treatment or treatment.
- a small molecule kinase inhibitor, an immune checkpoint regulator, and a receptor tyrosine kinase inhibitor that block the TGF- ⁇ signaling pathway may be administered simultaneously, sequentially or separately, and a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, Types of immune checkpoint modulators and receptor tyrosine kinase inhibitors, types of tumors, administration methods and doses are as defined above.
- the invention provides 6-(6-(6-methylpyridin-2-yl)- administered in combination with a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof).
- a PD-1 inhibitor preferably an anti-PD-1 antibody or fragment thereof.
- the salt may be used for preparing a drug for preventing or treating melanoma, colon cancer, bladder cancer, sarcoma, breast cancer, cervical cancer, head and neck squamous cell carcinoma, or liver cancer.
- the invention provides 6-(6-(6-methylpyridin-2-yl)- administered in combination with a PD-L1 inhibitor (preferably an anti-PD-L1 antibody or fragment thereof).
- a PD-L1 inhibitor preferably an anti-PD-L1 antibody or fragment thereof.
- the use of the salt may be for preparing a medicament for preventing or treating melanoma.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-, administered in combination with a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof).
- a CTLA-4 inhibitor preferably an anti-CTLA-4 antibody or fragment thereof.
- the salt may be used for preparing a drug for preventing or treating melanoma, colon cancer, sarcoma, breast cancer, cervical cancer, squamous cell cancer of the head and neck, or liver cancer.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1, 2-a] imidazol-5-yl) -[1,2,4] triazole [1,5-a] pyridine or a pharmaceutically acceptable salt thereof is used for colorectal cancer, cervical cancer, head and neck squamous cell cancer or It may be used for preparing a drug for preventing or treating liver cancer.
- the invention provides 6-(6-(6-methylpyridine-2) administered in combination with lenvatinib and a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof).
- a PD-1 inhibitor preferably an anti-PD-1 antibody or fragment thereof.
- the salt may be used for preparing a drug for preventing or treating colorectal cancer, cervical cancer, squamous cell cancer of the head and neck, or liver cancer.
- the invention provides 6-(6-(6-methylpyridine-2) administered in combination with lenvatinib and a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof).
- CTLA-4 inhibitor preferably an anti-CTLA-4 antibody or fragment thereof.
- it may be used for preparing a drug for preventing or treating colorectal cancer, cervical cancer, squamous cell cancer of the head and neck, or liver cancer.
- the invention provides a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) and a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof) 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,
- a PD-1 inhibitor preferably an anti-PD-1 antibody or fragment thereof
- a CTLA-4 inhibitor preferably an anti-CTLA-4 antibody or fragment thereof
- 2,4] triazole [1,5-a] pyridine or a pharmaceutically acceptable salt thereof it may be used for preparing a drug for preventing or treating colorectal cancer, cervical cancer, head and neck squamous cell cancer or liver cancer there is.
- the present invention provides a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway; And a kit for preventing or treating tumors comprising instructions for administering a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway in combination with at least one selected from immune checkpoint modulators and receptor tyrosine kinase inhibitors.
- a small molecule kinase inhibitor, an immune checkpoint regulator, and a receptor tyrosine kinase inhibitor that block the TGF- ⁇ signaling pathway may be administered simultaneously, sequentially or separately, and a small molecule kinase inhibitor that blocks the TGF- ⁇ signaling pathway, Types of immune checkpoint modulators and receptor tyrosine kinase inhibitors, types of tumors, administration methods and doses are as defined above.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof; and 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,2,4] Including instructions for administering triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof in combination with a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) , melanoma, colorectal cancer, bladder cancer, sarcoma, breast cancer, cervical cancer, head and neck squamous cell cancer, or liver cancer may be prevented or treated.
- a PD-1 inhibitor preferably an anti-PD-1 antibody or fragment thereof
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof; and 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,2,4] Instructions for administering triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof in combination with a PD-L1 inhibitor (preferably an anti-PD-L1 antibody or fragment thereof) , kits for preventing or treating melanoma.
- a PD-L1 inhibitor preferably an anti-PD-L1 antibody or fragment thereof
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof; and 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,2,4]
- Instructions for administering triazole [1,5-a] pyridine or a pharmaceutically acceptable salt thereof in combination with a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof) , melanoma, colon cancer, sarcoma, breast cancer, cervical cancer, head and neck squamous cell carcinoma, or liver cancer may be prevented or treated.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5 -yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof; and 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,2,4]
- Prevention of colorectal cancer, cervical cancer, squamous cell carcinoma of the head and neck or liver cancer including instructions for administering triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof in combination with lenvatinib or a kit for treatment.
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof; and 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,2,4] Handling instructing administration of triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof in combination with lenvatinib and a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) It may be a kit for preventing or treating colorectal cancer, cervical cancer, squamous cell carcinoma of the head and neck, or liver cancer, including instructions.
- a PD-1 inhibitor preferably an anti-PD-1 antibody or fragment thereof
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5 -yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof; and 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,2,4] Handling instructing administration of triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof in combination with lenvatinib and a CTLA-4 inhibitor (preferably an anti-CTLA-4 antibody or fragment thereof) It may be a kit for preventing or treating colorectal cancer, cervical cancer, squamous cell carcinoma of the head and neck, or liver cancer, including instructions.
- CTLA-4 inhibitor preferably an anti-CTLA-4 antibody or fragment thereof
- the invention provides 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5- yl)-[1,2,4]triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof; and 6-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H-imidazo[1,2-a]imidazol-5-yl)-[1,2,4] Triazole[1,5-a]pyridine or a pharmaceutically acceptable salt thereof is mixed with a PD-1 inhibitor (preferably an anti-PD-1 antibody or fragment thereof) and a CTLA-4 inhibitor (preferably an anti-PD-1 antibody or fragment thereof). CTLA-4 antibody or fragment thereof) and a kit for preventing or treating colorectal cancer, cervical cancer, head and neck squamous cell carcinoma, or liver cancer, including an instruction manual instructing administration.
- a PD-1 inhibitor preferably an anti-PD-1 antibody or fragment thereof
- Example 1.1.1 Preparation of melanoma mouse model and test drug
- mice 40 female C57BL/6 mice aged 6 to 8 weeks were purchased from Orient Bio, and 1 x 10 6 B16F10 cell line (KCLB, #80008) was subcutaneously injected into the right flank of the mouse to transplant the cancer cell line.
- KCLB 1 x 10 6 B16F10 cell line
- the B16F10 cell line transplantation day was set as Day 0, and the tumor volume was measured on Day 9 (Day 9). Day 9 tumor volume mean and deviation were matched and mice were sorted.
- Example 1.1.2 Dosage of test drug, measured variables and statistical analysis method
- mice sorted in Example 1.1.1 were assigned to the control group (oral administration of vehicle), compound 1 oral administration group, intraperitoneal administration of anti-PD-1 antibody, or anti-PD-1 antibody and compound 1 combination administration group, B16F10 cell line transplantation Drug administration was started on the 9th day, and the test was terminated on the 24th day from the drug administration day.
- the dose and administration method of the drug administered for each group are shown in Table 1 below, and the dose per subject is 5 ml/kg in both oral (p.o) and intraperitoneal (i.p.) administration.
- mouse tumor volume and body weight were measured twice a week.
- the mouse tumor volume was calculated as (tumor length (L) X tumor width (W) X tumor width (W)) ⁇ 2, where the tumor length (L) is the longest tumor dimension, and the tumor width (W ) is the longest tumor dimension perpendicular to L.
- the tumor volume of an individual mouse exceeds 3000 mm 3 , the test was terminated by euthanasia of the mouse.
- the tumor volume of the anti-PD-1 antibody alone administration group was 45% lower than the tumor volume measured in the control group, and the tumor volume of the Compound 1 alone administration group The volume was 44% lower than the tumor volume measured in the control group, whereas the tumor volume of the anti-PD-1 antibody and Compound 1 combination administration group was 74% lower than the tumor volume measured in the control group.
- the tumor volume of the group administered with Compound 1 in combination with the anti-PD-1 antibody was at a statistically significant level compared to the anti-PD-1 antibody alone or Compound 1 alone administration group. It was found to have a difference (i.e., p ⁇ 0.001 and p ⁇ 0.05) (see Figure 1).
- mice 90 8-week-old female C57BL/6 mice were purchased from Orient Bio, and a melanoma mouse model was prepared by the method used in preparing the melanoma mouse model in Example 1.1.1.
- the B16F10 cell line transplantation day was set as Day 0, and the tumor volume was measured on Day 4 (Day 4). Mice were grouped by matching the mean and deviation of the day 4 tumor volume.
- Example 1.1.1 Using the vehicle and PBS used in Example 1.1.1 as carriers, a mixture of mouse anti-IgG2b antibody (BioXCell) and PBS, a mixture of mouse anti-PDL1 antibody (BioXCell) and PBS, a mixture of Compound 1 and vehicle, and LY2157299 (Chembo Pharma ) and a vehicle mixture were prepared.
- Example 1.2.2 Dosage of test drug, measured variables and statistical analysis method
- mice sorted in Example 1.2.1 were administered with a control group (combined administration of vehicle and anti-IgG2b antibody and PBS mixture), vehicle and anti-PDL1 antibody administration group, anti-PDL1 antibody and compound 1 (low dose: 15 mg/kg/day , High dose: 30 mg/kg/day) combination administration group or anti-PDL1 antibody and LY2157299 (low dose: 75 mg/kg/day, high dose: 150 mg/kg/day) combination administration group, B16F10 cell line transplantation date 4
- the drug was administered from the first day to the 21st day, and the test was terminated on the 22nd day.
- the dosage and administration method of the administered drug for each group are shown in Table 2 below, and the dose per subject was 10 ml/kg in both oral (p.o) and intraperitoneal (i.p.) administration.
- the tumor volume of the mouse was measured at intervals of 2 days from the day of drug administration, and the tumor volume was measured by necropsy on the day of test termination. At this time, the mouse tumor volume was calculated in the same way as the tumor volume calculation method of Example 1.1.2.
- the body weight of the mice was measured on days 4, 7, 11, 14, 18, and 21 based on the date of transplantation of the B16F10 cell line. Changes in tumor volume and body weight in each group were statistically analyzed using Tukey's multiple comparison after ANOVA test.
- the statistical significance compared to the control group administered with the vehicle and anti-IgG2b antibody was statistically analyzed using Dunnett's multiple comparison after ANOVA test.
- Statistical significance between the group administered with the test drug mouse anti-PD-L1 antibody alone and the group administered with the combination of Compound 1 and anti-PD-L1 antibody on day 22 from the date of B16F10 cell line transplantation was analyzed by Student's t-test.
- anti-PD from the 7th day of drug administration i.e., the 10th day from the B16F10 cell line transplantation date
- 19th day 22nd day from the cell line transplantation date
- -L1 antibody alone group low-dose Compound 1 and anti-PD-L1 antibody combination group
- high-dose Compound 1 and anti-PD-L1 antibody combination group high-dose LY2157299 and anti-PD-L1 antibody combination group
- LY2157299 and anti-PD-L1 antibody combination group showed significant tumor growth inhibition compared to the control group It was found to have an effect (see Figure 3).
- mice 40 female C57BL/6 mice aged 6 to 8 weeks were purchased from Orient Bio, and 1 x 10 6 B16F10 cell line (KCLB, #80008) was subcutaneously injected into the right flank of the mouse to transplant the cancer cell line.
- KCLB 1 x 10 6 B16F10 cell line
- the B16F10 cell line transplantation day was set as Day 0, and the tumor volume was measured on Day 9 (Day 9). Day 9 tumor volume mean and deviation were matched and mice were sorted.
- mice anti-CTLA-4 antibody BioXCell, clone #9D9
- PBS mixture and Compound 1 and vehicle mixture were prepared as test drugs.
- Example 1.3.2 Dosage of test drug, measured variables and statistical analysis method
- mice sorted in Example 1.3.1 were assigned to the control group (orally administered vehicle), compound 1 oral administration group, intraperitoneal administration group of anti-CTLA-4 antibody or anti-CTLA-4 antibody and compound 1 combination administration group, B16F10 cell line transplantation day
- the drug was administered from the baseline day 9 to the 21st day, and the test was terminated on the 22nd day.
- the dose and administration method of the drug administered for each group are shown in Table 3 below, and the dose per subject is 5 ml/kg in both oral (p.o) and intraperitoneal (i.p.) administration.
- mice tumor volume and body weight were measured twice a week. At this time, the mouse tumor volume was calculated in the same way as the tumor volume calculation method of Example 1.1.2. On the other hand, when the tumor volume of an individual mouse exceeds 3000 mm 3 , the test was terminated by euthanasia of the mouse.
- the compound 1 and anti-CTLA-4 antibody combination administration group was found to have a superior tumor growth inhibitory effect compared to the vehicle administration group, the compound 1 administration group, or the anti-CTLA-4 antibody administration group alone (see FIG. 6(a)). ).
- the tumor volume of the group administered with Compound 1 in combination with the anti-CTLA-4 antibody was statistically significant compared to the anti-CTLA-4 antibody alone or Compound 1 alone administration group. It was found to have a difference of (i.e., p ⁇ 0.01) (see Figure 6 (b)).
- CT26 cell lines murine colon cancer cells
- the CT26 cell line transplantation day was set as Day 0, and the tumor volume was measured on Day 7 (Day 7).
- Day 7 the average tumor volume was found to be 50 mm 3 , and 110 animals were selected, excluding individuals whose tumor volume was significantly larger or smaller than the average tumor volume.
- Example 2.2 Dosage of test drug, measured variables and statistical analysis method
- mice selected in Example 2.1 were assigned to the groups shown in Table 4 below, and vehicle or drug was administered, and drug administration was initiated on the 7th day from the cell line inoculation date, and the test was performed on the 27th day from the drug administration date. ended.
- the dose was 5 ml/kg for both oral (p.o.) and intraperitoneal (i.p.) administration.
- mice tumor volume and body weight were measured twice a week. At this time, the mouse tumor volume was calculated in the same way as the tumor volume calculation method of Example 1.1.2. On the other hand, when the tumor volume of an individual mouse exceeds 3000 mm 3 , the test was terminated by euthanasia of the mouse.
- Example 2.3.1 Combination Administration of Compound 1 with Anti-PD-1 Antibody and Combination of Compound 1 with Anti-CTLA-4 Antibody
- the tumor volume of the anti-PD-1 antibody and Compound 1 combination administration group was measured at a value lower than that of the anti-PD-1 antibody alone administration group, the Compound 1 administration group alone, or the control group administered only with the vehicle throughout the test period (Fig. 8(a)).
- the tumor volume of the anti-PD-1 antibody alone administration group was 4.8% lower than the tumor volume measured in the control group
- the Compound 1 alone administration group The tumor volume of was 59% lower than the tumor volume measured in the control group, whereas the tumor volume of the anti-PD-1 antibody and Compound 1 combination administration group was 77% lower than the tumor volume measured in the control group.
- the anti-PD-1 antibody and Compound 1 combination administration group showed the lowest tumor weight, and the Compound 1 alone administration group The difference in tumor weight between the groups administered with the combination of anti-PD-1 antibody and Compound 1 was found to be statistically significant (see FIG. 8(b)).
- the tumor volume of the high-dose anti-CTLA antibody and Compound 1 combination administration group was measured at a value lower than that of the high-dose anti-CTLA antibody alone administration group, the Compound 1 administration group alone, or the control group administered only with the vehicle throughout the test period (Fig. 9(a)).
- the tumor volume of the high-dose anti-CTLA-4 antibody alone administration group was 27% lower than that of the control group, and the tumor volume of the Compound 1 alone administration group was 59% lower than that of the control group, whereas the tumor volume of the high-dose anti-CTLA-4 antibody and Compound 1 combination administration group was 77% lower than that of the control group (see FIG. 9(b)).
- the tumor volume observed in the groups administered with the combination of anti-PD-1 antibody, low-dose anti-CTLA-4 antibody and Compound 1 was significantly different from the control group administered only with vehicle throughout the test period, the anti-PD-1 antibody alone administration group, Tumor volume observed in low-dose anti-CTLA-4 antibody alone, Compound 1 alone, combination of anti-PD-1 and high-dose anti-CTLA-4, and compound 1 and low-dose anti-CTLA-4 antibody combination It was found to be lower (see Fig. 10).
- the tumor volume of the combination-administered group of anti-PD-1 antibody, low-dose anti-CTLA-4 antibody and Compound 1 was 88% lower than that of the control group administered only with the vehicle, compared to the tumor volume of the control group administered with only the vehicle.
- Anti-PD-1 antibody alone administration group low-dose anti-CTLA-4 antibody alone administration group, Compound 1 alone administration group, Compound 1 and low-dose anti-CTLA-4 antibody combination administration group, and anti-PD-1 antibody and high-dose anti-CTLA
- the tumor volume observed in the group administered with the combination of -4 antibodies was 4.8%, 23%, 59%, 60%, and 63% lower, respectively (see Fig. 10).
- Example 2.3.2 Combination of Compound 1 and Lenvatinib or Combination of Compound 1 and Lenvatinib with an anti-PD-1 antibody and/or an anti-CTLA-4 antibody
- the tumor volume of the lenvatinib and Compound 1 combination administration group was the anti-PD-1 antibody alone administration group, the lenvatinib alone administration group, the Compound 1 administration group alone, the lenvatinib and anti-PD-1 antibody combination administration group, or
- the tumor volume of the group administered with lenvatinib, compound 1 and anti-PD-1 antibody in combination was lower than that of the group administered with lenvatinib and compound 1 combination. It was found (see Fig. 11).
- the tumor volume of the lenvatinib, anti-CTLA-4 antibody, and Compound 1 combination administration group was significantly higher than that of the anti-CTLA-4 antibody alone group, the lenvatinib alone administration group, and the lenvatinib and anti-PD-1 group throughout the test period. It was measured as a value lower than that of the antibody combination administration group, the lenvatinib and anti-CTLA-4 antibody combination administration group, and the control group (see FIG. 12).
- the lenvatinib and compound 1 combination administration group and the lenvatinib, compound 1 and anti- The tumor volume reduction in the group administered with the PD-1 antibody in combination was 68% and 90%, respectively.
- the tumor volume reduction in the group administered with lenvatinib, compound 1, and anti-CTLA-4 antibody in combination was 82% compared to the tumor volume in the control group administered only with the vehicle.
- Example 2.5 Experiment to confirm whether compound 1 and lenvatinib's mechanism of action overlap ( in vitro )
- hPBMC Human peripheral blood mononuclear cells
- hPBMC human peripheral blood mononuclear cells
- hPBMCs were plated on coated 6-well plates. In order to increase the reactivity of hPBMCs, they were cultured for 5 days at 37° C. under 5% carbon dioxide humidified incubator conditions. The hPBMC cultured for 5 days were seeded in a 96-well plate at a concentration of 1x10 5 cells/well.
- TGF- ⁇ was added and cultured for 1 hour.
- Anti-CD3 antibody/anti-CD28 antibody-coated microbeads were treated with hPBMCs at a cell:beads ratio of 2:1, and hPBMCs were stimulated for 72 hours. After 72 hours, the supernatant was collected and subjected to conventional IFN- ⁇ ELISA. The amount of IFN- ⁇ produced in each group was measured. Data analysis was performed using Prism 5 (GraphPad Software, Inc.), and statistical analysis was performed using One-way ANOVA and Tukey's multiple comparison.
- lenvatinib is known to have insufficient anticancer effects in an endothelial cell anergy environment accompanied by a decrease in binding proteins such as VCAM-1 generated on the surface of vascular endothelial cells. Therefore, when compound 1 is used in combination with lenvatinib having a different mechanism of action, the anticancer effect of lenvatinib can be supplemented and improved.
- mice 60 female BALB/C mice aged 6 to 8 weeks were purchased from Vital River Laboratories Research Model and Services.
- a cancer cell line was transplanted by subcutaneous injection of 1 X 10 6 WEHI-164 cell line (Murine sarcoma cell) into the right flank of the mouse.
- the date of WEHI-164 cell line transplantation was set as Day 0, and the tumor volume was measured on Day 7 (Day 7).
- the average tumor volume was found to be 53 mm 3 , and mice with a significantly larger or significantly smaller tumor volume than the average tumor volume were excluded to keep the average and deviation of each group constant. selected.
- 0.9% physiological saline was prepared as a vehicle, and a mixture of anti-PD-1 antibody (BioXCell) and PBS, a mixture of anti-CTLA-4 antibody (BioXCell) and PBS, and a mixture of Compound 1 and vehicle were prepared as test drugs.
- Example 3.2 Dosage of test drug, measured variables and statistical analysis method
- mice selected in Example 3.1 were treated as a control group, an anti-PD-1 antibody administration group, a compound 1 administration group, an anti-CTLA-4 antibody administration group, a compound 1 and anti-PD-1 antibody combination administration group, or a compound 1 and anti-CTLA-4 administration group. They were assigned to each antibody combination administration group. Drugs were administered from the 7th day to the 23rd day based on the transplantation date of the WEHI-164 cell line. The dosage and administration method of the drug administered for each group are shown in Table 5 below, and the dosage was 5 ml/kg for both oral (p.o.) and intraperitoneal (i.p.) administration.
- Example 3.3 Tumor growth inhibitory effect and remission rate
- the anti-PD-1 antibody and Compound 1 combination-administered group showed a smaller tumor volume than the anti-PD-1 antibody-only group, the Compound 1-administered group, or the vehicle-administered control group throughout the test period (see FIG. 14 ).
- the tumor volume of the anti-PD-1 antibody alone administration group measured on the 16th day from the start of drug administration was 64% smaller than that of the control group, and the tumor volume of Compound 1 alone administration group was 71% smaller than that of the control group.
- the tumor volume of the anti-PD-1 antibody and Compound 1 combination administration group was 98% smaller than that of the control group, and the anti-PD-1 antibody and Compound 1 combination administration group and Compound 1 administration group alone or the anti-PD-1 antibody and Compound 1 administration group
- the difference in tumor volume between the groups administered with the PD-1 antibody alone was statistically significant (p ⁇ 0.05) (see FIG. 14).
- the complete tumor remission rate was 20% when the anti-CTLA-4 antibody was administered alone compared to the vehicle-administered control group, and the complete tumor remission rate was 30% when Compound 1 was administered alone compared to the vehicle-administered control group, and the anti-CTLA-4 compared to the vehicle-administered control group
- An 80% tumor complete remission rate was observed when the antibody and Compound 1 were administered in combination.
- the difference between the tumor complete remission rate of the anti-CTLA-4 antibody and Compound 1 combination treatment group and the anti-CTLA-4 antibody alone or Compound 1 alone was statistically significant (p ⁇ 0.05), and the anti-CTLA-4 antibody and Compound 1 combination administration was found to have an excellent tumor growth inhibitory effect (see FIG. 15).
- mice 60 female BALB/C mice aged 6 to 8 weeks were purchased from Vital River Laboratories Research Model and Services.
- a cancer cell line was implanted by subcutaneously injecting 3 X 10 5 4T1 cell lines (murine breast cancer cells) into the right flank of the mouse.
- the date of transplantation of the 4T1 cell line was set as Day 0, and the tumor volume was measured on Day 6 (Day 6). It was found that the average tumor volume on day 6 was 52 mm 3 , and mice with a significantly larger or significantly smaller tumor volume than the average tumor size were excluded to keep the average and deviation of each group constant. selected.
- 0.9% physiological saline was prepared as a vehicle, and a mixture of anti-PD-1 antibody (BioXCell) and PBS, a mixture of anti-CTLA-4 antibody (BioXCell) and PBS, and a mixture of Compound 1 and vehicle were prepared as test drugs.
- Example 4.2 Dosage of test drug, measured variables and statistical analysis method
- mice selected in Example 4.1 were treated as a control group, an anti-PD-1 antibody administration group, a compound 1 administration group, an anti-CTLA-4 antibody administration group, a compound 1 and anti-PD-1 antibody combination administration group, or a compound 1 and anti-CTLA-4 administration group. They were assigned to each antibody combination administration group. Drugs were administered from day 6 to day 30 based on the date of transplantation of the 4T1 cell line. The dosage and administration method of the drug administered for each group are shown in Table 6 below, and the dosage is 5 ml/kg for both oral (p.o.) and intraperitoneal (i.p.) administration.
- Example 4.3 Tumor growth inhibitory effect and remission rate
- the group administered with the combination of anti-PD-1 antibody and Compound 1 showed a smaller tumor volume than the control group administered with anti-PD-1 antibody alone, Compound 1 alone, or vehicle administration throughout the test period (see FIG. 17(a)).
- the tumor volume of the anti-PD-1 antibody alone administration group measured on the 23rd day from the cell line inoculation was increased by 2.6% compared to the control group, and the tumor volume of the Compound 1 alone administration group was 16% higher than that of the control group. It appeared at a reduced level (see Fig. 17 (b)).
- the tumor volume of the anti-PD-1 antibody and Compound 1 combination administration group was reduced by 35% compared to the control group, and the difference in tumor volume between the anti-PD-1 antibody and Compound 1 combination administration group and the control group showed that the p-value was less than 0.001 when analyzed by two-way ANOVA, and the p-value was less than 0.01 when analyzed using one-way ANOVA and Tukey's multiple comparison test, indicating that the tumor volume was reduced at a statistically significant level compared to the control group. (See Fig. 17).
- the tumor volume of the vehicle-administered control group measured on the 23rd day from the day of cell line inoculation, the tumor volume was reduced by 17% when the anti-CTLA-4 antibody was administered alone, and Compound 1 alone administration compared to the tumor volume of the vehicle-administered control group While the tumor volume was reduced by 16%, it was observed that the tumor volume of the anti-CTLA-4 antibody and Compound 1 combination-administered group was reduced by 46% compared to the tumor volume of the vehicle-administered control group.
- the difference in tumor volume between the anti-CTLA-4 antibody and Compound 1 combination treated group and the control group was analyzed by two-way ANOVA analysis, one-way ANOVA, and Tukey's multiple comparison test.
- the p-value was less than 0.001, indicating that the tumor volume was reduced at a statistically significant level compared to the control group (see FIG. 18).
- mice Seven-week-old C3H/HeN female mice were purchased from Orient Bio.
- a cancer cell line was implanted by subcutaneous injection of 2.5 X 10 5 MBT2 cell line (Murine bladder cancer cell) into the right flank of the mouse. MBT2 cell line transplantation day was set as Day 0, and tumor volume was measured on Day 6 (Day 6). It was found that the average tumor volume on day 6 was 50 mm 3 , and mice with significantly larger or significantly smaller tumor volumes than the average tumor size were excluded to keep the average and deviation of each group constant. selected.
- physiological saline 0.9% physiological saline was prepared as a vehicle, anti-PD-1 antibody (BioXCell) and PBS mixture, and Compound 1 and vehicle mixture were prepared as test drugs.
- Example 5.2 Dosage of test drug, measured variables and statistical analysis method
- mice selected in Example 5.1 were assigned to a control group, an anti-PD-1 antibody administration group, a compound 1 administration group, or a compound 1 and anti-PD-1 antibody combination administration group, respectively.
- Drugs were administered from day 6 to day 28 based on the MBT2 cell line transplantation date.
- the dosage and administration method of the drug administered for each group are shown in Table 7 below, and the dosage is 10 ml/kg for both oral (p.o.) and intraperitoneal (i.p.) administration.
- mice tumor volume and body weight were measured three times a week.
- the tumor volume was measured in the same way as the method of measuring the tumor volume in Example 1.1.2.
- the test is terminated by euthanasia of the mouse, and if the tumor volume is less than 1/4 of the euthanasia standard tumor volume, the response to the drug Classified as a responder.
- the survival rate was calculated using the date of death of each mouse or the date of euthanasia when the mass volume exceeded 1500 mm 3 , and a significant difference in survival rate was analyzed by Kaplan-Meier survival curve analysis (Prism 5.0).
- a 6- to 8-week-old female C57BL/6 mouse is purchased, and a cancer cell line is implanted by subcutaneously injecting 3 x 10 6 U14 cell line into the flank of the mouse.
- mice were assigned to the groups shown in Table 9 below, and vehicles or drugs were administered, and drug administration was initiated on the 7th day from the cell line inoculation date, and the test was terminated on the 27th day from the drug administration start date,
- the administration volume for oral (po) administration and the administration volume for intraperitoneal (ip) administration are both 5 ml/kg.
- mouse tumor volume and body weight are measured twice a week.
- the mouse tumor volume is calculated in the same way as the tumor volume calculation method of Example 1.1.2.
- the test is terminated by euthanasia of the mouse.
- a 6- to 8-week-old female C57BL/6 mouse is purchased, and a cancer cell line is implanted by subcutaneously injecting 3 x 10 6 MOC1 cell line into the flank of the mouse.
- the date of MOC1 cell line transplantation is set as Day 0, the tumor size is measured on Day 7 (Day 7), and the mice are classified so that there is no difference between deviations in the average tumor volume of 50 mm 3 on Day 7 for each group.
- mice were assigned to the groups shown in Table 10 below, and vehicles or drugs were administered, and drug administration was initiated on the 7th day from the cell line inoculation date, and the test was terminated on the 27th day from the drug administration start date,
- the administration volume for oral (po) administration and the administration volume for intraperitoneal (ip) administration are both 5 ml/kg.
- mouse tumor volume and body weight were measured twice a week. At this time, the mouse tumor volume is calculated in the same way as the tumor volume calculation method of Example 1.1.2. On the other hand, when the tumor volume of an individual mouse exceeds 3000 mm 3 , the mouse is euthanized to end the test.
- a 6- to 8-week-old female BALB/C mouse is purchased, and a cancer cell line is implanted by subcutaneously injecting 1 x 10 6 H22 (murine liver cancer cell line) cell line into the flank of the mouse.
- H22 human liver cancer cell line
- mice were assigned to the groups shown in Table 11 below, and vehicles or drugs were administered, and drug administration was initiated on the 7th day from the cell line inoculation date, and the test was terminated on the 27th day from the drug administration start date,
- the administration volume for oral (po) administration and the administration volume for intraperitoneal (ip) administration are both 5 ml/kg.
- mouse tumor volume and body weight were measured twice a week. At this time, the mouse tumor volume is calculated in the same way as the tumor volume calculation method of Example 1.1.2. Meanwhile, when the tumor volume of an individual mouse exceeds 3000 mm 3 , the test is terminated by euthanasia of the mouse.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
약물 | 마리 수 |
비히클 1일 2회(p.o.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
약물 | 마리 수 |
비히클 1일 2회(p.o.) + 12.5 mg/kg 마우스 항-IgG2b 항체 주 2회(i.p.) | 15 |
비히클 1일 2회(p.o.) + 마우스 항-PD-L1 항체 12.5 mg/kg 주 2회(i.p.) | 15 |
마우스 항-PD-L1 항체 12.5 mg/kg 주 2회(i.p.) + 화합물 1* 15 mg/kg/day, 1일 2회(p.o., 7.5 mg/kg/회) *상기 용량은 염을 포함한 상태로 계산됨 |
15 |
마우스 항-PD-L1 항체 12.5 mg/kg 주 2회(i.p.) + 화합물 1* 30 mg/kg/day, 1일 2회(p.o., 15 mg/kg/회) *상기 용량은 염을 포함한 상태로 계산됨 |
15 |
마우스 항-PD-L1 항체 12.5 mg/kg 주 2회(i.p.) + LY2157299 75 mg/kg/day, 1일 2회(p.o., 37.5 mg/kg/회) |
15 |
마우스 항-PD-L1 항체 12.5 mg/kg 주 2회(i.p.) + LY2157299 150 mg/kg/day, 1일 2회(p.o., 75 mg/kg/회) |
15 |
약물 | 마리 수 |
비히클 1일 2회(p.o.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
약물 | 마리 수 |
비히클 1일 2회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항 PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.)+ 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.)+ 마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
약물 | 마리수 |
비히클 1일 2회(p.o) | 10 |
마우스 항-PD-1 항체 10 mg/kg 주 1회(i.p.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 주 1회 (i.p.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 주 1회(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 10 mg/kg 주 1회 (i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
약물 | 마리수 |
비히클 1일 2회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일마다 투여(i.p.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일마다 투여 (i.p.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일마다 투여 (i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일마다 투여 (i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
약물 | 마리수 |
비히클 1일 2회(p.o.) | 12 |
화합물 1 15 mg/kg, 1일 2회(p.o.) | 11 |
마우스 항-PD-1 항체 12.5 mg/kg 주 2회(i.p.) | 9 |
마우스 항-PD-1 항체 12.5 mg/kg 주 2회 (i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
13 |
약물 | 반응개체 비율 |
비히클 1일 2회(p.o) | 0/12(0%) |
화합물 1 15 mg/kg, 1일 2회(p.o.) | 1/11(9%) |
마우스 항-PD-1 항체 12.5 mg/kg 주 2회(i.p.) | 2/9(22%) |
마우스 항-PD-1 항체 12.5 mg/kg 주 2회 (i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
4/13(33%) |
약물 | 마리 수 |
비히클 1일 2회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항 PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
약물 | 마리 수 |
비히클 1일 2회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항 PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
약물 | 마리 수 |
비히클 1일 2회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
화합물 1 50 mg/kg, 1일 2회(p.o.) | 10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) | 10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) | 10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) | 10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항 PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 렌바티닙 10 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 마우스 항-CTLA-4 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 마우스 항-CTLA-4 항체 3 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
렌바티닙 10 mg/kg, 1일 1회(p.o.) + 마우스 항-PD-1 항체 10 mg/kg 3일에 한번(i.p.) + 화합물 1 50 mg/kg, 1일 2회(p.o.) |
10 |
Claims (20)
- TGF-β(transforming growth factor-β) 신호 전달 경로를 차단하는 저분자 키나아제 억제제를 포함하는, 종양을 예방하거나 치료하기 위한 약학 조성물로서, 상기 TGF-β 신호 전달 경로를 차단하는 저분자 키나아제가 면역 관문 조절제 및 수용체 티로신 키나아제 억제제 중 1종 이상과 조합하여 투여되는, 약학 조성물.
- 제1항에 있어서, 상기 TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제가 하기로 이루어진 군에서 선택되는 화합물 또는 이의 약학적으로 허용되는 염인 약학 조성물:1) 1-[6-(6-메틸-피리딘-2-일)-5-퀸옥살린-6-일-2,3-다이하이드로-이미다조[1,2-a]이미다졸-1-일]-에탄온;2) 6-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-퀸옥살린;3) 6-[2-(6-메틸-피리딘-2-일)-5,6,7,8-테트라하이드로-이미다조[1,2-a]피리미딘-3- 일]-퀸옥살린;4) 6-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-퀴놀린;5) 6-[2-(6-메틸-피리딘-2-일)-5,6,7,8-테트라하이드로-이미다조[1,2-a]피리미딘-3-일]-퀴놀린;6) 2-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-티에노[3,2-c]피리딘;7) 6-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-벤조티아졸;8) 5-벤조[b]티오펜-5-일-6-(6-메틸-피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;9) 6-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)-[1,2,4]트리아졸[1,5-a]피리딘;10) 5-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-벤즈옥사졸;11) 4-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-퀴놀린;12) 5-벤조[1,3]다이옥솔-5-일-6-(6-메틸-피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;13) 5-(2,3-다이하이드로-벤조[1,4]다이옥신-6-일)-6-(6-메틸-피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;14) 7-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-2-피라졸-1-일-퀸옥살린;15) 다이메틸-(2-{7-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-퀸옥살린-2-일옥시}-에틸)-아민;16) 2-메톡시-7-[2-(6-메틸-피리딘-2-일)-6,7-다이하이드로-5H-이미다조[1,2-a]이미다졸-3-일]-퀸옥살린;17) 5-(3,5-다이메톡시페닐)-6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;18) N,N-다이메틸-4-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)아닐린;19) 4-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)벤조나이트릴;20) 2-메틸-6-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)퀴놀린;21) 4-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)아닐린;22) N-(4-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)페닐)아세트아마이드;23) N-(4-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)페닐)메탄설폰아마이드;24) 3급-부틸 (4-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)페닐)카바메이트;25) 5-(4-(4-메틸피페라진-1-일)페닐)-6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;26) 4-(4-(6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-5-일)페닐)모폴린;27) 6-(6-메틸피리딘-2-일)-5-(m-톨릴)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;28) 5-(4-메톡시페닐)-6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;29) 6-(6-메틸피리딘-2-일)-5-(4-(트라이플루오로메틸) 페닐)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;30) 6-(6-메틸피리딘-2-일)-5-(4-(메틸티오) 페닐)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;31) 5-(3-플루오로-4-메톡시페닐)-6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;32) 5-(4-플루오로페닐)-6-(6-메틸피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸;33) 1-아세틸-6-(6-메틸-피리딘-2-일)-5-티에노[3,2-c]피리딘-2-일-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-카복실산 에틸 에스터;34) 6-(6-메틸-피리딘-2-일)-5-티에노[3,2-c]피리딘-2-일-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-카복실산 에틸 에스터;35) [6-(6-메틸-피리딘-2-일)-5-티에노[3,2-c]피리딘-2-일-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-일]-메탄올;36) 1-아세틸-6-(6-메틸-피리딘-2-일)-5-티에노[3,2-c]피리딘-2-일-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-카보나이트릴;37) 6-(6-메틸-피리딘-2-일)-5-티에노[3,2-c]피리딘-2-일-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-카보나이트릴;38) 6-(6-메틸-피리딘-2-일)-5-티에노[3,2-c]피리딘-2-일-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-카복실산 아마이드;39) (6-(6-메틸피리딘-2-일)-5-(티에노[3,2-c]피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-일)메탄아민; 및40) N-((6-(6-메틸피리딘-2-일)-5-(티에노[3,2-c]피리딘-2-일)-2,3-다이하이드로-1H-이미다조[1,2-a]이미다졸-2-일)메틸)아세트아마이드.
- 제1항에 있어서, 상기 TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제가 면역 관문 조절제와 조합하여 투여되는, 약학 조성물.
- 제1항 또는 제3항에 있어서, 상기 면역 관문 조절제가 프로그램된 사멸-리간드 1(programmed death-ligand 1: PD-L1) 억제제, 프로그램된 세포 사멸 단백질(programmed cell death protein 1: PD-1) 억제제 및 세포독성 T-림프구-연관 항원 4(cytotoxic T-lymphocyte-associated antigen 4: CTLA-4) 억제제로 이루어진 군으로부터 선택되는 어느 하나인 약학 조성물.
- 제1항 또는 제3항에 있어서, 상기 면역 관문 조절제가1) PD-L1 단백질에 특이적으로 결합하는 압타머, 펩타이드, 항체 및 상기 항체의 항원 결합 단편으로 이루어진 군에서 선택되는 1종 이상;2) PD-1 단백질에 특이적으로 결합하는 압타머, 펩타이드, 항체 및 상기 항체의 항원 결합 단편으로 이루어진 군에서 선택되는 1종 이상; 및3) CTLA-4 단백질에 특이적으로 결합하는 압타머, 펩타이드, 항체 및 상기 항체의 항원 결합 단편에서 선택되는 1종 이상에서 선택되는 어느 하나인 약학 조성물.
- 제1항 또는 제3항에 있어서, 상기 면역 관문 조절제가 항-PD-L1 항체 또는 이의 항원 결합 단편; 항-PD-1 항체 또는 이의 항원 결합 단편; 또는 항-CTLA-4 항체 또는 이의 항원 결합 단편인 약학 조성물.
- 제1항에 있어서, 상기 TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제가 수용체 티로신 키나아제 억제제와 조합하여 투여되는, 약학 조성물.
- 제1항 또는 제7항에 있어서, 상기 수용체 티로신 키나아제 억제제가 VEGF 수용체, FGF 수용체, PDGFRα, KIT, RET 및 c-Met에서 선택되는 1종 이상의 티로신 키아나제의 억제제인, 약학 조성물.
- 제1항 또는 제7항에 있어서, 상기 수용체 티로신 키나아제 억제제가 VEGF 수용체, FGF 수용체, PDGFRα, KIT, RET 및 c-Met에서 선택되는 1종 이상의 티로신 키아나제의 기능을 억제하는 화합물이거나, 또는 상기 티로신 키나아제 단백질에 특이적으로 결합하는 압타머, 펩타이드, 항체 및 상기 항체의 항원 결합 단편에서 선택되는 1종 이상인, 약학 조성물.
- 제7항에 있어서, TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제가 추가로 면역 관문 조절제와 조합하여 투여되는, 약학 조성물.
- 제1항에 있어서, 상기 종양이 흑색종, 육종, 뇌종양, 유방암, 부신암, 갑상선암, 췌장암, 뇌하수체암, 교모세포종, 안구암, 질암, 외음부암, 자궁경부암, 자궁내막 암종, 자궁암, 난소암, 식도암, 위암, 결장암, 직장암, 간암, 담낭암, 담관암종, 폐암, 고환암, 전립선암, 음경암, 구강암, 기저암, 타액선암, 인두암, 피부암, 신장암, 윌름즈 종양, 방광암, 두경부암, 두경부 편평세포암, 간세포암, 충수암, 기관지암, 융모막암종, 척삭종, 상의세포종, 위장관 기질 종양 (GIST), 신경내분비암 및 요도암으로 이루어진 군에서 선택되는 약학 조성물.
- 제1항에 있어서, 상기 종양이 고형 종양인 약학 조성물.
- 제1항에 있어서, 경구투여용인 약학 조성물.
- 제1항에 있어서, 상기 TGF-β 신호 전달 경로를 차단하는 저분자 키나아제가 면역 관문 조절제 및 수용체 티로신 키나아제 억제제 중 1종 이상과 동시에 투여되거나 개별적으로 투여되는 약학 조성물.
- TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제; 및면역 관문 조절제 및 수용체 티로신 키나아제 억제제 중 1종 이상을 포함하는, 종양을 예방하거나 치료하기 위한 조합물.
- TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제; 및면역 관문 조절제 및 수용체 티로신 키나아제 억제제 중 1종 이상을 포함하는, 종양을 예방하거나 치료하기 위한 약학 조성물.
- TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제; 및면역 관문 조절제 및 수용체 티로신 키나아제 억제제 중 1종 이상을 대상체에 투여하는 단계를 포함하는, 대상체의 종양을 예방하거나 치료하는 방법.
- 제17항에 있어서, 상기 투여는 동시 또는 개별적으로 이루어지는 방법.
- 면역 관문 조절제 및 수용체 티로신 키나아제 억제제 중 1종 이상과 조합하여 투여되는 TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제의 용도로서, 종양을 예방하거나 치료하기 위한 약제를 제조하기 위한 용도.
- TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제; 및TGF-β 신호 전달 경로를 차단하는 저분자 키나아제 억제제를 면역 관문 조절제 및 수용체 티로신 키나아제 억제제 중 1종 이상과 조합하여 투여하는 것을 지시하는 취급 설명서를 포함하는, 종양을 예방하거나 치료하기 위한 키트.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280064928.9A CN117999077A (zh) | 2021-07-28 | 2022-07-28 | 用于预防或治疗肿瘤的药物组合物及其用途 |
EP22849912.5A EP4378460A1 (en) | 2021-07-28 | 2022-07-28 | Pharmaceutical composition for preventing or treating tumor, and use thereof |
CA3227334A CA3227334A1 (en) | 2021-07-28 | 2022-07-28 | Pharmaceutical composition for preventing or treating tumor, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0099500 | 2021-07-28 | ||
KR20210099500 | 2021-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023008936A1 true WO2023008936A1 (ko) | 2023-02-02 |
Family
ID=85087969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/011149 WO2023008936A1 (ko) | 2021-07-28 | 2022-07-28 | 종양 예방 또는 치료용 약학 조성물 및 이의 용도 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4378460A1 (ko) |
KR (1) | KR20230017756A (ko) |
CN (1) | CN117999077A (ko) |
CA (1) | CA3227334A1 (ko) |
WO (1) | WO2023008936A1 (ko) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011056494A1 (en) * | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2015119930A1 (en) * | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
KR20170122799A (ko) * | 2015-03-02 | 2017-11-06 | 리겔 파마슈티칼스, 인크. | TGF-β 억제제 |
KR20170123593A (ko) * | 2015-04-07 | 2017-11-08 | 주식회사 메드팩토 | 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 |
KR101938368B1 (ko) | 2011-07-13 | 2019-01-14 | 주식회사 티움바이오 | Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸 |
KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
WO2021142448A2 (en) * | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
-
2022
- 2022-07-28 EP EP22849912.5A patent/EP4378460A1/en active Pending
- 2022-07-28 CA CA3227334A patent/CA3227334A1/en active Pending
- 2022-07-28 WO PCT/KR2022/011149 patent/WO2023008936A1/ko active Application Filing
- 2022-07-28 CN CN202280064928.9A patent/CN117999077A/zh active Pending
- 2022-07-28 KR KR1020220094192A patent/KR20230017756A/ko unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011056494A1 (en) * | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
KR101938368B1 (ko) | 2011-07-13 | 2019-01-14 | 주식회사 티움바이오 | Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸 |
WO2015119930A1 (en) * | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
KR20170122799A (ko) * | 2015-03-02 | 2017-11-06 | 리겔 파마슈티칼스, 인크. | TGF-β 억제제 |
KR20170123593A (ko) * | 2015-04-07 | 2017-11-08 | 주식회사 메드팩토 | 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 |
KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
WO2021142448A2 (en) * | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
Non-Patent Citations (2)
Title |
---|
FISHMAN ET AL.: "Medicine", 1985, J.B. LIPPINCOTT CO. |
MURPHY ET AL.: "Treatment, and Recovery", 1997, PENGUIN BOOKS U.S.A., INC., article "Informed Decisions: The Complete Book of Cancer Diagnosis" |
Also Published As
Publication number | Publication date |
---|---|
KR20230017756A (ko) | 2023-02-06 |
CA3227334A1 (en) | 2023-02-02 |
CN117999077A (zh) | 2024-05-07 |
EP4378460A1 (en) | 2024-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9695178B2 (en) | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | |
EP3625224B1 (en) | N-substituted indole derivatives | |
WO2021167389A1 (ko) | 엠토르 신호전달 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물 | |
CA3173955A1 (en) | Methods of using myt1 inhibitors | |
AU2019418259B2 (en) | Anticancer compositions comprising immune checkpoint inhibitors | |
WO2020171649A1 (ko) | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 | |
WO2020171646A1 (ko) | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 | |
US6245817B1 (en) | NPY5 receptor antagonists and methods for using same | |
US11919854B2 (en) | P2RX7 modulators in therapy | |
WO2023008936A1 (ko) | 종양 예방 또는 치료용 약학 조성물 및 이의 용도 | |
CA3087807A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | |
WO2018147612A1 (ko) | 암의 전이 억제 및 치료용 조성물 | |
KR20200016877A (ko) | 표적 치료제를 포함하는 병용 요법 | |
WO2022010322A1 (ko) | 나프토퀴논계 화합물 및 면역관문 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2022098083A1 (ko) | Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 | |
WO2024063566A1 (ko) | 종양 혈관 파괴용 약학 조성물 | |
US20210186978A1 (en) | Combination therapy | |
WO2023018747A1 (en) | Inhibitors of hypoxia-inducible factors | |
TW202421108A (zh) | 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物 | |
AU2020415060A1 (en) | Antitumor drug for use in combination with immune checkpoint inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22849912 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3227334 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2024504990 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022849912 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022849912 Country of ref document: EP Effective date: 20240228 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280064928.9 Country of ref document: CN |